ORIGINAL RESEARCH

Open Access WILEY

Identification and characterization of protective CD8⁺ T-epitopes in a malaria vaccine candidate SLTRiP

Afshana Quadiri | Inderjeet Kalia | Mohammad Kashif | Agam P. Singh 💿

Infectious Diseases Laboratory, National Institute of Immunology, New Delhi, India

Correspondence

Agam P. Singh, Infectious Diseases Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110067, India. Email: singhap@nii.ac.in

Funding information

Department of Biotechnology, Ministry of Science and Technology, Grant/Award Number: BT/PR21569/ NNT/28/1234/2017; SERB, Ministry of Science and Technology, Grant/Award Number: EMR/2015/001546

Abstract

Introduction: Efforts are required at developing an effective vaccine that can inhibit malaria prevalence and transmission. Identifying the critical immunogenic antigens and understanding their interactions with host proteins forms a major focus of subunit vaccine development. Previously, our laboratory showed that SLTRiP conferred protection to the liver stage of *Plasmodium* growth in rodents. In the follow-up of earlier research, we demonstrate that SLTRiP-mediated protection is majorly concentrated in specific regions of protein.

Method: To identify particular protective regions of protein, we synthesized multiple nonoverlapping fragments from SLTRiP protein. From this, we designed a panel of 8-20mer synthetic peptides, which were predicted using T-epitope-based prediction algorithm. We utilized the IFN- γ enzyme-linked immunosorbent spot assay to identify immunodominant peptides. The latter were used to immunize mice, and these mice were challenged to assess protection.

Results: The protective polypeptide fragment SLTRiP C3 and SLTRiP C4 were identified, by expressing and testing multiple fragments of PbSLTRiP protein. The immune responses generated by these fragments were compared to identify the immunodominant fragment. The T-epitopes were predicted from SLTRiP protein using computer-based algorithms. The in vitro immune responses generated by these peptides were compared with each other to identify the immunodominant T-epitope. Immunization using these peptides showed significant reduction in parasite numbers during liver stage.

Conclusion: Our findings show that the protective efficacy shown by SLTRiP is localized in particular protein fragments. The peptides designed from such regions showed protective efficacy equivalent to whole protein. The sequence conservation analysis with human *Plasmodium* species also showed that these peptides were conserved. In conclusion, these peptides or their equivalent from other *Plasmodium* species could impart protection against malaria in their respective hosts too. Our

Abbreviation: P. berghei, Plasmodium berghei, PBS, phosphate-buffered saline.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. Immunity, Inflammation and Disease published by John Wiley Sons Ltd.

studies provide a basis for the inclusion of these peptides in clinical vaccine constructs against malaria.

K E Y W O R D S

liver-stage malaria, T-cell epitopes, vaccine

1 | INTRODUCTION

Malaria is a mosquito-borne infectious disease affecting annually an estimated 212 million people worldwide, the causative agent being an Apicomplexan parasite of genus *Plasmodium.*¹ The disease manifests in a broad range of clinical symptoms varying from moderate symptoms like fever and diarrhea to life-threatening symptoms, which include severe anemia, respiratory distress, renal impairment, coma, and even death. Despite high mortality, no licensed vaccine that can provide 100% (sterile) protection against Plasmodium infection exists. The complicated genetic structure and high antigen diversity of Plasmodium make malaria vaccine generation a daunting task. The situation has become perilous with the increasing resistance of Plasmodium against common antimalarial drugs.^{2,3} In fact, resistance against artemisinin has also been reported from various parts of Asia and Africa.^{4,5} In addition, most known therapeutic drugs against Plasmodium restrict or kill parasites during its blood stage. The need for an effective vaccine against malaria that targets both blood as well as liver stage has become indispensable for the control and eradication of malaria.⁶ This is necessary as some Plasmodium species persist as dormant hypnozoites in the liver, which are activated anytime from days to years after primary infection, causing relapse of blood-stage parasite.

The vaccines designed against microbes belong to one of the three categories-killed parasite, attenuated parasite, and subunit vaccines. Live radiation-attenuated Plasmodium berghei sporozoites (RAS) were the first vaccines against malaria that gave full sterile protection against the challenge of live sporozoites and is considered the "gold standard" for development of malaria pre-erythrocytic stage subunit vaccines.7-11 Immunization using chemically and or genetically attenuated malaria parasites have been shown to provide immunity against multiple strains of Plasmodium parasite.¹²⁻¹⁴ However, the approach faces the challenges of manufacture cost, storage, and distribution of parasite, thus limiting the use of this approach in endemic areas. Conversely, a subunit vaccine includes one or multiple protein antigen that may or may not be coupled to immunogenic and protective epitopes.

A very few subunit vaccines against different infectious diseases have been licensed and are being used. These include tetanus, diphtheria and pertussis (TDP) toxins, hepatitis B surface antigen, and vaccine against human papilloma virus.¹⁵ *Plasmodium* proteins have been assessed in murine models, for the development of therapeutic vaccines against vector- or host-specific malarial stages. The synthesis of a peptide-based vaccine called SPf66, with apparent efficacy against monkeys generated enormous interest for field trials in Africa to demonstrate protection.¹⁶ The studies with SPf66 also led to the development of field technologies to evaluate different vaccine candidates.

Malaria sporozoites express exoerythrocytic stage-specific virulent proteins important for productive hepatocyte invasion. These include CSP, EXP1, TRAP, SPECT1, SPECT2, CelTOS, UIS4, and PPLP1 and many other proteins.¹⁷ These proteins have been studied for their protective efficacy, some of which, like circumsporozoite protein (CSP) and TRAP, are already in the advanced stages of vaccine development.¹⁸ The major sporozoite coat protein, CSP, is well characterized and widely used as a model antigen. The central repeat (R) region and the T-cell epitopes (T) of Plasmodium falciparum CSP combined with hepatitis B surface antigen given along with the AS01 adjuvant system (RTS,S/AS01), provides partial protective immunity against malaria infection primarily through high levels of antibodies.¹⁹ The protection is limited to a maximum percentage of 40 to 50 and the antigen needs to be improved for its efficacy, by combining it with new antigens and adjuvants.²⁰ The identification of Plasmodium surface protein-circumsporozoite protein led to an optimistic prediction of a possible subunit vaccine against malaria. However, validation of the abilities of vaccine antigen candidates for boosting immune responses and providing 100% sterile protection in humans is still in process. Multiple tests are done to increase the efficacy of partially effective antigens through assessments of new adjuvants, delivery platforms, and/or identifying new candidate antigens. Epitopes from MSP, LSA-1, and CSP have been tested alone and as part of multiepitope antigen.²¹ Therefore, epitope-enhanced immunogens, expressing multiple copies of linear B and T-cell epitopes from candidate antigens could be an important strategy to increase the protective efficacy of these vaccines.

In a previous work, we reported the protective efficacy of a novel antigen SLTRiP.²² SLTRiP immunization affected the growth of parasites within hepatocytes by delaying the prepatent period by 3 to 4 days. Immunized mice displayed protection subsequent to sporozoite challenge and exhibited 10 000-fold less parasites 18S ribosomal RNA (rRNA) copy numbers in liver thus emphasizing the vaccine potential of SLTRiP.²² These data support the potential of SLTRiP as a target antigen for malaria vaccine development. In addition, this protection was majorly attributed to cell-mediated immune system. In this paper, we aim to identify immunodominant and subdominant T-cell epitopes, interferon γ (IFN- γ) secretion by T cells against those epitopes. In addition, we attempted to identify epitopes involved in protection. Studies have shown that the T-cell epitopes bind to peptide-binding groove on MHC molecules, which has hydrophobic regions. To fit this groove, T-cell epitopes need hydrophobic amino acids while hydrophilic regions are needed for interaction with T-cell receptor. Bioinformatics approach to classify epitopes using Parker hydrophilicity prediction was employed to identify hydrophobic regions, which are likely to contain high-scoring T-cell epitopes.23 The study reports a protein antigen and its protective regions that can facilitate the development of a second-generation vaccine against malaria.

2 | MATERIALS AND METHODS

2.1 | Ethics statement, experimental animals, and parasites

Six- to eight-week-old male/female C57BL/6 mice (H2^b) were used in all animal experiments. The animal work was conducted in accordance with National Institute of Immunology's (NII) Institutional Animal Ethics Committee (IAEC) rules. The IAEC approval number for the project is NII-312/13. Animals were injected with ketamine/xylazine intraperitoneally for short-term anesthesia. At the end of each experiment, the anesthetized mice were killed humanely by cervical dislocation.

2.2 | Parasite cycle

Six- to eight-week-old male/female C57BL/6 mice were used for growing parasites. *P. berghei* ANKA parasites were cycled between mice and *Anopheles stephensi* mosquitoes. Mosquitoes (3-5 days old, female) were starved overnight and fed on infected mice. These infected mosquitoes were kept at 19°C, 70% to 80% relative humidity, 12 hours light cycle and fed on cotton pads soaked in 20% sucrose solution for 18 days post infected blood meal. After 18 days, sporozoites were obtained from dissection of salivary glands from infected mosquitoes. For this, the infected mosquitoes were first washed with 50% ethanol, followed by PBS, and dissected in RPMI 1640 media containing 10% fetal bovine serum. To obtain sporozoites, salivary glands were ground gently and centrifuged at 800 rpm for 4 minutes to remove mosquito tissue. The number of sporozoites present in per unit volume (mL) was determined by counting in a hemocytometer.

2.3 | Bioinformatics analysis

Parker hydrophilicity prediction was used to distinguish between the hydrophilic and hydrophobic regions of the protein. The region above the threshold value are generally hydrophilic (shown in yellow) while the regions below the threshold are hydrophobic (shown in green). The epitopes of SLTRiP were predicted using Immune Epitope Database (IEDB) analysis resource, http://tools.immuneepitope.org/ mhci. This tool takes an amino acid sequence, or a set of sequences to determine possible MHC class I binding peptides. It establishes the probability of a particular amino acid sequence to form a T-cell epitope by assigning a score or percentile rank. The lower the assigned score to a particular amino acid sequence, the greater is the probability of that region to form T-cell epitopes. The prediction method allows choosing from a number of MHC class I binding prediction methods. Based on the availability of predictors and formerly observed predictive performance, this selection uses the best possible method for a given MHC molecule. Currently for peptide:MHC-I binding prediction, for a given MHC molecule, IEDB Recommended uses the Consensus method consisting of ANN, SMM, NetMHCpan, and CombLib methods. We employed IEDB recommended 2.19 for our epitope prediction. The epitope predictions were limited to peptides of H2^b allele and specific to MHC class I. Variablelength peptides were chosen based on position in protein and percentile rank.

2.4 | Primer designing

The amino acid sequence of SLTRiP gene of *P. berghei* was scanned for hydrophobic regions. Primers were designed from hydrophilic region such that four fragments incorporating the whole gene were generated with no overlapping regions. Primers with *Bam*HI and *Xho*I sites were used to facilitate cloning of fragments in pGEX6P1 vector and express fragments of open reading frame of SLTRiP fused in-frame to the 3' end of the glutathione *S*-transferase (GST) protein.

2.5 | Expression and purification of SLTRiP fragments

The individual polypeptide fragments (C2, C3, C4, C5) were induced by addition of isopropyl 1-thio-D-galactopyranoside

(IPTG) to a final concentration of 1 mM when the bacterial culture reached 0.5-0.7 OD₆₀₀, followed by incubation of 12 hours at 37°C for C2; 18 hours at 18°C for C3 and C4; and 18 hours at 25°C for C5. The cells were harvested at 8000 rpm for 10 minutes at 4°C and suspended in buffer A (100 mM Tris, 250 mM NaCl, 10% glycerol, 0.5 mM EDTA, 0.05% Triton X-100, pH 8.0) with 0.02 mg/mL lysozyme and protease inhibitor mixture to make complete lysis buffer. The suspension was sonicated at 4°C (ice-cold) for 10 minutes. The sample was cleared by centrifugation at 12 000 rpm for 20 minutes at 4°C. The supernatant obtained was loaded onto a prepacked 5-mL GST-FF column and washed with 10 column volumes of buffer A. The protein was eluted with buffer A containing 15% v/v of buffer B (50 mM reduced glutathione) using AKTA explorer chromatography system. The purity was observed to be more than 95% in case of C3, C4, and C5. An additional step of gel filtration chromatography was employed for purification of C2. Yields were typically in the range of 3 to 4 mg of purified protein/L of bacterial culture for C2 and C5 but 0.5-1 mg/L for C3 and C4.

2.6 | Immunization with purified SLTRiP polypeptide fragments and SLTRiP peptides

C57BL/6 mice, aged 6 to 8 weeks were immunized; priming was done with 50 μ g of polypeptide in complete Freund's adjuvant (Sigma, India) per mouse. In the three subsequent boosters, the amount of polypeptide used was 25 μ g per mouse mixed with incomplete Freund's adjuvant (Sigma). Boosts were given on days 15, 21 and 28 post-priming. The control group was immunized in an identical manner with GST protein.

2.7 | Peptide synthesis

The studies were initially carried out with a panel of long protein fragments spanning the complete sequence of the SLTRiP protein. Later 15 peptides consisting of 9 to 16 amino acids, spanning the protective protein fragments were used to define minimal T-cell epitopes. The peptides were synthesized commercially by Bio Basic (Canada) at more than 80% purity.

2.8 | Enzyme-linked immunosorbent assay

Culture supernatants from in vitro stimulated splenocytes were collected after 60 hours of incubation. Secreted

cytokines were measured by enzyme-linked immunosorbent assay (ELISA) using an eBiosciences kit, following manufacturer's instructions. The purified anticytokine antibody was added to the wells of enhanced protein binding ELISA plate, sealed, and incubated at 4°C overnight. The next day, the antibody solution was removed and the plate was blocked using blocking buffer for 1 to 2 hours at room temperature (RT) to prevent nonspecific binding. Plate was washed three times with PBST ($1 \times$ phosphate-buffered saline with Tween detergent). Biotinylated anticytokine detection antibody was added, sealed, and the plate was incubated at RT for 1 hour. It was washed again three times with 1× PBST. Secondary antibody conjugated with HRP was added to the wells, sealed, and incubated again at RT for 30 minutes. The plate was washed five times with PBST and developed using TMB (3,3',5,5'-tetramethylbenzidine) substrate until color starts to appear. Optical density was measured at 450 nm in a microplate reader (Tecan M200, UK).

2.9 | Ex vivo IFN-γ enzyme-linked immunosorbent spot

Ex vivo enzyme-linked immunosorbent spot (ELISpot) assay was done for peptide-stimulated splenocytes following manufacturer's (BD Biosciences) protocol. Capture antibody diluted in coating buffer was added to each well of an ELISpot plate and stored at 4°C. Next day, antibody was discarded; plate washed and blocked with a blocking solution for 1 to 2 hours at RT. Splenocyte suspension was prepared and added at different dilutions (10⁵-10⁶ cells/mL) to wells of ELISpot plate. The cells were activated using proper mitogen and antigen. ELI-Spot plate was incubated at 37°C, in a 5% CO₂ and humidified incubator for 24 hours. The cell suspension was aspirated and plate was washed three times with wash buffer. Detection antibody was prepared and added to ELISpot plate. The plate was incubated at RT for 2 hours, followed by washing three times again with wash buffer. Secondary Ab-HRP enzyme conjugate was added to the plate and incubated for 1 hour at RT. The plate was washed five times with wash buffer and finally, substrate solution was added to each well of ELISpot plate. Spot development was monitored for 5 to 60 minutes and reaction was stopped, by washing wells with deionized water to prevent overdevelopment of spots, else it may give high background. The plate was air-dried at RT for 2 hours or overnight until it was completely dry. The plate was stored in a sealed plastic bag in the dark, until analysis. Spots were enumerated using an ELISpot plate reader (AID iSpot ELHR04, Germany).

3 | RESULTS

3.1 | Generation of polypeptide fragments

We aimed to identify immunodominant and subdominant T-cell epitopes involved in protection against sporozoite challenge. For this, gene fragment clones were designed as an approach to predict the minimal protective region in **SLTRiP** (Figure 1A). Parker hydrophilicity prediction method was employed to distinguish hydrophobic regions from hydrophilic regions. We observed the regions designated as SLTRiP C1, SLTRiP C3, SLTRiP C4, and SLTRiP C5 had hydrophobic regions but SLTRiP C2 was majorly hydrophilic in nature (Figure 1B). The protein SLTRiP, mentioned in the work or used for immunization experiments starts from N-terminus, amino acids 85 to 413. The exon 1, referred to as fragment SLTRiP C1 was added in later annotations to the protein and the peptides from this fragment have been used as negative control in peptide stimulation studies. The protein hydrophilic regions were used to design primers that corresponded to individual polypeptide fragment. This was done to ensure that none of the possible T-cell epitopes are fragmented. The individual gene fragments were amplified using, Escherichia coli codon-optimized SLTRiP gene as template and PCR primers (Table 1). The gene fragments were cloned in the bacterial expression vector pGEX6p1, which contains a GST tag at its N-terminus (Figure 1C). The clones were confirmed and the individual gene fragments were expressed as GST-tagged fusion protein or protein fragments. The fusion protein fragments were purified using the GSTbinding column. The purity of all fragments was observed to be above 95% from sodium dodecyl sulfate-polyacrylamide gel electrophoresis image (Figure 1D). SLTRiP C2 fragment being majorly hydrophilic, gave yield in the range of 2 to 3 mg of purified protein per liter of the bacterial culture. The other fragments give yield in the range of 1 mg/L of bacterial culture, one of the reasons for low yield being the continuous stretches of hydrophobic amino



FIGURE1 Construction of gene fragment clones and expression in *Escherichia coli*. A, Gene fragment clones were constructed from the SLTRiP gene, which was codon-optimized for expression in *E. coli*, and the fragments were labeled as SLTRiP C2, SLTRiP C3, SLTRiP C4, and SLTRiP C5. B, Parker hydrophilicity prediction was done to identify hydrophobic regions, likely to contain T-cell epitopes. Primers were designed from the gene corresponding to the hydrophilic regions of the protein. C, The individual gene fragments were amplified using SLTRiP codon-optimized gene as template and were cloned in pGEX6P1 vector. D, The individual gene fragments were expressed and purified as glutathione *S*-transferase (GST)-tagged protein or protein fragments using the GST-binding column

TABLE 1 Primers for SLTRiP fragment cloning

Primer designation	Primer sequence, 5'-3'
SLTRiP-C2FP	CGAT-GGATCC-GAATACAGCGACGATGAGTA-3
SLTRiP-C2RP	TCAT-CTCGAG-AGAGATCACGCTGGATTTGC-3
SLTRiP-C3FP	CGAT-GGATCC-TTCATCAAAAAAAAAACCGACGA-3
SLTRiP-C3RP	TCAT-CTCGAG-CAGGTTGTTCCAACGGTTG-3
SLTRiP-C4FP	CGAT-GGATCC-CAGACCGAAAACGAAAACAAC-3
SLTRiP-C4RP	TCAT-CTCGAG-CTCAATGTTGTAGATGTAGTG-3
SLTRiP-C5FP	CGAT-GGATCC-ATCCTGTGCAACAAAGAGAA-3
SLTRiP-C5RP	TCAT-CTCGAG-GATGTTAGAGCGTTCGCTAG-3

Note: Restriction sites are shown in bold letters.

acids as observed in Parker hydrophilicity prediction. The purified fragments qualified for subsequent analysis of their abilities to stimulate splenocytes.

3.2 | Identification of immunodominant SLTRiP fragment

Studies have shown the role of cytokines in modulating immune responses. To demonstrate the most immunodominant fragment in terms of IFN- γ secretion, an in vitro IFN- γ ELISA was conducted. For this, the mice were immunized with SLTRiP protein (Figure 2A). The splenocytes from SLTRiP-immunized mice were cultured and stimulated with individual fragments/polypeptides in vitro. The supernatant of culture was collected and quantitated for IFN- γ concentration. The cultures stimulated with SLTRiP C2 and SLTRiP C5 showed IFN- γ secretion on stimulation, which was more than the control. However, significantly increased secretion of IFN- γ was observed in cultures stimulated with SLTRiP C3 and SLTRiP C4, which was comparable with that of SLTRiP protein stimulation (Figure 2B), establishing these two as immunodominant polypeptides/fragments.

3.3 | SLTRiP fragments immunization and sporozoite challenge assay

In the next set of experiments, we compared the protective efficacy of SLTRiP fragments by mice immunization experiment. Groups of 12, females 6-week-old C57BL6 mice were immunized with SLTRiP fragments subcutaneously as shown in Figure 2A. Two weeks after the last boost, the mice were challenged with 5000 *P. berghei* ANKA sporozoites given intravenously. One set of mice was analyzed for parasite load in mice liver while the other set of mice (six mice) was monitored for emergence and growth of blood-stage parasite. The parasitemia levels

were observed by microscopic examination of Giemsastained thin blood smears prepared from day 3 post challenge and followed until the mice died. The parasitemia count for SLTRiP C3 and C4 showed a delay in



FIGURE 2 Identification of the immunodominant polypeptide. C57BL/6 mice aged 6 to 8 weeks were immunized with 25 µg of SLTRiP protein. A, The boosts were given after 2 weeks and the spleen was isolated, 2 weeks after the last boost. The splenocytes were stimulated in vitro with individual protein fragments for 2 days, in the presence of interleukin-2 (IL-2). The cell culture supernatants were collected and levels of interferon- γ (IFN- γ) were determined by enzyme-linked immunosorbent assay method. All data are means and standard errors based on six mice per group. B, ***P* < .01; using one-way analysis of variance Bonferroni's multiple comparison test. Positive, positive control stimulated with cell stimulation cocktail (Invitrogen); SLTRiP, mice stimulated with SLTRiP-full; C2, C3, C4, and C5, sets of mice stimulated separately with polypeptides (SLTRiP fragments) in vitro; US, unstimulated prepatent period of 4 and 3 days while SLTRiP C2 and C5 showed a delay of 0 and 2 days, respectively. The prepatent delay shown by SLTRiP C3 and SLTRiP C4 was comparable with full-length SLTRiP protein immunized mice (Figure 3A). Furthermore, a 3 log reduction in parasite 18S rRNA copy numbers was observed in mice immunized with SLTRiP C3 and SLTRiP C4; which is close to the reduction observed with SLTRiP protein. SLTRiP C5 showed nearly 2 log reduction, while SLTRiP C2 showed less than 0.5 log reduction in mice liver burden (Figure 3B). The survival assay showed an increased survival of 4 days in mice immunized with SLTRiP C3 and SLTRiP C4 while an increased survival of only 1 day was observed in SLTRiP C2- and C5-immunized mice compared with control (Figure 3C). Overall, the sporozoite challenge assay showed a decrease in parasite load, delay in prepatent period, and increased survival in mice immunized with SLTRiP C3 and SLTRiP C4, which was comparable with SLTRiP protein. These results indicate that the protection contributed by SLTRiP is located mostly in these fragments (C3 and C4) of SLTRiP.

3.4 | Immunogenicity and protective efficacy of putative T-cell epitopes

Bioinformatics approaches to identify T-cell epitopes, have been used in many infectious diseases for their inclusion in vaccines with success. Peptides joined as a string of beads were synthesized as a recombinant protein to immunize against *P. falciparum* epitopes. In this study, bioinformatics approach was used to screen for potential T-cell epitopes in SLTRiP and to identify T- epitopes with the potential to provide protection against P. berghei sporozoite challenge in mice. In this regard, 8-20mer consecutive peptides that encompass the entire protective gene fragments were synthesized using T cell-based algorithm. Table 2 shows the list of all peptides chosen from SLTRiP for use in in vitro stimulation and protection assay. IEDB tool was used for T-epitope prediction. Epitopes from SLTRiP fragments namely C1, C3, C4, and C5 were predicted using IEDB analysis and chemically synthesized. Their comparative location in protein is shown in Figure 4A.



FIGURE 3 SLTRiP fragments immunization and sporozoite challenge assay: (A) the Giemsa-stained slides showing the prepatent period of the parasite in mice immunized with SLTRiP and its fragments. The exoerythrocytic parasite burden (parasite 18S ribosomal RNA [rRNA] copy number) was quantified from the liver of mice immunized with SLTRiP or its fragments and challenged with wild-type sporozoites. B, The 18S rRNA copy numbers were not normalized with mice glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (control), as GAPDH values were equal in all the samples. C, The survival of immunized mice was calculated and plotted. The data are presented as means and standard error of the means of six mice per group. **P* < .05; using one-way analysis of variance Kruskal-Wallis test. Control, immunized with adjuvant only; GST, immunized with GST protein; SLTRiP, immunized with SLTRiP; C2, C3, C4 and C5, sets of mice immunized separately with SLTRiP fragments

TABLE 2 The table shows the list of	peptides selected from	protective fragments for in vitro stimulati	on and in vivo protection assay

SLTRiP		Peptide	Peptide		
fragment	Allele	label	sequence	Length	Percentile rank
		PEP101	NSKKQHSNLQYISYI	15	0.1
SLTRiP C1	H_2D^b	PEP102	YIFIYFFIFPSIPL	14	1.7
		PEP103	ILYSNVKHRLKTFL	14	0.57
SLTRiP C2	H_2D^b				
		PEP301	ICYFFDKKKTSYRKLTEYW K	20	18
SLTRiP C3	H_2D^b	PEP302	WQLLNLGIENVI	12	0.32
~	2	PEP303	IKKMIERNNAELE	13	0.97
		PEP304	GNKLK EKIYNRWNNL	15	15.5
		PEP305	LYAQYASLYKKI PSIEID	19	4.7
		PEP401	IKYAPN RNEYHV WQ	14	0.27
SLTRiP C4	H_2D^b	PEP402	WVQWKN KYRYHI	12	0.68
		PEP403	YIYNIE IL	8	0.8
		PEP501	IADNFVKN	8	28.8
SLTRiP C5	H_2D^b	PEP502	KNPQLRLWI	9	12
		PEP503	VKPFPRKKL	9	58

Note: Peptide length and percentile rank is given in the rightmost columns. IEDB recommended 2.19 was used for our epitope prediction. The percentile rank given corresponds to the sequences in red. The lower the assigned score to a particular amino acid sequence, the greater is the probability of that region to form T-cell epitopes.

Splenocytes were collected from SLTRiP-immunized mice and incubated with peptide at concentration 10 ng/well in a 96-well plate for 72 hours. Epitope-induced IFN- γ secretion was monitored by IFN- γ ELISA. An increase in the release of IFN- γ was observed in cells stimulated with peptides 302, 303, 304, and 401 (Figure 4B). A suboptimal increase was also observed in cells stimulated with peptides 305, 402, and 502. Similarly, splenocytes collected from SLTRiPimmunized mice were incubated with peptides at concentration 10 ng/well for 24 hours in an ELISpot plate. Epitopeinduced IFN- γ secretion was monitored by the formation of spots on membrane. An increase in number of IFN-y spots was observed in wells stimulated with peptides 302, 303, 304, 401, and 502 (Figure 4C), while comparatively moderate spots were also observed in wells stimulated with peptides 305 and 402. These results determined peptides 302, 303, 304,

401, and 502 as immunodominant peptides, and 305 and 402 as subdominant peptides. As fragment analysis had shown that most of SLTRiP-related protection is concentrated in fragment SLTRiP C3 and SLTRiP C4; peptides 302, 303, 304, 305, and 401 were further used for immunization to analyze them for their protective efficacy.

Groups of C57BL/6 mice (5-6 mice/group) aged 6 to 8 weeks were immunized with above mentioned immunodominant peptides. The immunization schedule was same as shown in Figure 2A and 50 or 25 μ g of peptides were used for priming and boosts, respectively. A week after the final boost, mice were challenged with 10 000 *P. berghei* ANKA sporozoites given via intravenous route. The burden of parasite in liver was quantified by measuring parasite 18S rRNA using real-time PCR analysis. PEP 302 showed 2 log reduction and PEP 303 showed 2.5 log reduction in parasite



FIGURE 4 SLTRiP T-cell epitope peptides characterization: splenocytes were collected from the immunized mice, cultured in presence of IL-2, and stimulated with peptides at concentration 10 ng/well for 3 days. A, The comparative location of peptides in protein is shown. B, Epitope-induced interferon- γ (IFN- γ) secretion was monitored by IFN- γ enzyme-linked immunosorbent assay. C, Epitope-induced IFN- γ spot formation was monitored by enzyme-linked immunosorbent spot assay by calculating the number of spots formed in each stimulated well. The decrease in pre-erythrocytic parasite burden (parasite 18S rRNA copy number) in the liver of mice immunized with peptides and challenged with wild-type sporozoites.was quantified. D, The 18S rRNA copy numbers were not normalized with mice glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control as the values for all GAPDH copy numbers were equal in all the samples. The data represented are means and standard error of the means based on six mice per group. **P* < .05; ***P* < .01; by one-way analysis of variance Kruskal-Wallis test. Control, mice immunized with adjuvant; PEP, peptide

18S rRNA copy numbers while PEP 304 and PEP 401 showed only 1.5 log reduction. PEP 305 showed no reduction in mice liver burden as compared with control immunized mice. (Figure 4D). The significant reduction in parasite burden in PEP 302- and PEP 303-immunized mice confirmed these peptides as dominant protective epitopes (Figure 5).

3.5 | T-epitope conservation among the human parasites

To identify the conservation of T-epitopes, the sequences of these immunodominant peptides were aligned with homologous proteins in human *Plasmodium* species using ClustalW tool. The aligned sequences showing identical amino acids with no gaps were considered conserved across species. PEP 302 showed nearly 90% conservation in amino acids across species followed by PEP 303 which also showed considerable amino acid conservation. Furthermore, the protective T-epitopes (peptides 302, 303, 304, and 401) contained the positionally conserved tryptophans (W), which is one of the features of SLTRiP protein. Besides tryptophan, other hydrophobic amino acids (V, I, L, F) and charged amino acids (K, R, E, D) conservation is evident in protective T-epitopes (Figure 5). Nonprotective T-epitope (peptide 305) lacks the conservation of amino acids observed in protective T-epitopes.

4 | DISCUSSION

The current research on a malaria subunit vaccine is majorly built on recombinant sporozoite protein, RTS,S. A number of alternatives exist for inducing immune responses, which include attenuated or inactive parasites. Although considerable efforts are being made at overcoming the limitations associated with irradiated and genetically attenuated sporozoites, the approach of formulating parasite recombinant proteins in an adjuvant, ought to be explored. Furthermore,

Access	W	I	L	E	Y

Open

PEP302 PENNKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PKNK_1324300 PFDAVKA_0701000 PKNK_1324300 PFDAVKA_0701000 PKNK_1324300 PFDAVKA_0701000 PFDAVKA_0701000 PKNK_1324300 PFDAVKA_0701000 PFDAVKA_0701000 PKNK_1324300 PFDAVKA_0701000 PFDAVKA_0701000 PKNK_1324300 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000 PFDAVKA_0701000		PEP 302
PBANKA_0701000 PF307_050500 PF307_050500 PF00G1_0505900 PKH_1324300 PKH_1324300 PEP307_050500 PF00G1_05015900	PEP302	WOLLNLGIENVI
PFD07_080000 TNTTSLLS0DERGEVELEDWK:NEMTINMODTFEERMOLLUKELGERGENELEGENKES PVD01_0504200 -NNTETSLLS0DERGEVELEDWK:NEMTINDORDERWOLLUKETEERGENELEGENKES PoGGH01_00158900 -NNTETSLL-SDEEGEVELEDWK:NEMTIDIORDERWOLLUKTEERGENELEGENKES PKHL_1324300 -NNTETSLL-SDEEGEVELEDWK:NEMTIDIORDERWOLLUKTEERGENELEGENKES PEP300 -NNTETSLL-SDEEGEVELEDWK:NEMTIFHIOTEERWOLLUKTEERGENELEGENKES PBNRK_0701000 GKISVISLIKNISSENUMENTHENKENNENTHINGENENDELEGENKENEERGENKESD PVD01_0504200 ODNOAVMSYLAELPEELEEWK:NEMTIFHINGENEWOLLUKUTEERGENEERGENKEED PVD01_0504200 ODNOAVMSYLAELPEELEEWK:NEMTIFHISTERWOLLUKUTEERGENKEED PVD01_0504200 ODNOAVMSYLAELPEELEEWK:NEMTIFHISTERWOLLUKUTEERGENKEED PVD01_0504200 TEEIE-VEIPEDEEELEEWK:NEMTIFHISTERWOLLUKUTEERGENKEED PV001_0504200 TEEIE-VEIPEDEEELEEWK:NEMTIFHISTERWOLLUKUTEERGENKEED PW001_05015900 TWILKERITHEELEEKK:NEMTERGENKEERGENKEED PF107_0803500 TWILTGQAAHMISSINLYA-QYASLYKKITPSIEIDNUTERGENKEERMODORNEERGE PF107_0803500 TWILTGQAAHMISSINLYA-QYASLYKKITPSIEIDNUTERGENKEERMODORNEERGE PF107_0803500 TWILTGQAHKMENSWITTINDIDEEYDDNYKSYKKITTENSEGELMEELKEYNEENGELE PF107_0803500 TWILTGQAHKMENSWITTINDIDEEYDDNYKSYKKITTENSEGELMEELKEYNEENGELE PF107_0803500 TWILTKENTYNEENGELEEKKKINEERGENEEKKYNTERGODORGUKKSYNGTINGNONK	PBANKA 0701000	GGK I SVI SLIKKT SYRKLT EYNKRRRWKKYLKKVDNEWOLLNLG I ENVI SKHI ERNNAEL
PVP01_0504200 DNQAVMSYLARL-PERELEWK:NQEWKYVEENTEREWQLLWINNERK, SVENTERSKOKEL, PvoGB01_00158900 NTERTEVETPRDERELEWK:NSEWKINPLDKALILWITEREK, SVENTERSKOKEL, PKHL_1324300 NTERTEVETPRDERELEWK:NSEWKINPLDKALILWITEREK, SVENTERSKOKEL, PKHL_1324300 NTERTEVETPRDERELEWK:NSEWKINPVNITEREWQLLWINGEDEK, SVENTERSKOKEL, PF0303 NEVLKALEG-ATTERELEWK:NSEWKINPVNITEREWQLLWINGEDEK, SVENTERSKOKEL PFD304 NEVLKALEG-ATTERELEWK:NSEWKINPVNITEREWQLUNUTERERSKOKELGEN:NKLEGKNIKED PF00501_0515900 FEETE-VETPEDERELEEWKINGEVKINWEITEREVQLUNUTERERVONTEKSKOKELGEN:NKLEGKNIKED PF00501_0515900 FEETE-VETPEDERELEEWKINGEVKINMETEREVQLUNUTEREVQUINVEKKINKED PKNH_1324300 OKINEVLKALEGAMEERELEWKINGEVKINMETEREVQLUNUTEREVQUINVEKKINKEDEL PKNH_1324300 OKINEVLKALEGAMEERELEWKINGEVKINMETEREVQUINVEKKINKERKINKEDINVERENKINKENTER PF307_0830500 FEETE-VETPEDERELEEWKINGEVKINMENTEREVQUINVEREVKINKEDINVEREVKINKENTEREVQUINVERENKINKEDINVEREVKINKENTEREVQUINVEREVKINKEDINVEREVKINKENTEREVQUINVEREVKINKEDINVEREVKINKENTEREVQUINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVEREVKINKEDINVER	PF3D7 0830500	INETSLLSSDEEGEVNLEDWKKNEWIKWNDETEEEWOLLKLWLEGEKKWLEGKNKEY
PocGB0_00159900 PKHL_324300 PKHL_324400 PK	PVP01 0504200	-DNOAVMSYLAEL-PERELEEWKNOEWKKYMEN I EEEWOLLNIWI EEEKONWI ESKOKEL
PEDG01_05015900 PKNH_1324300 -NRKEVEQELPEDEELEKNK:NENTINPINGT_NENQLINVQIEDEK_KW.EEKDKEL PKNH_1324300 -NRKEVEQELPEDEELEKNK:NENKKINEKKINEKKINKENDILINVIEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKENNITEKE	PocGH01 00158900	-NTERIEVEIPEDERELEEWENKEWENPIDENEWOLLNIWMEGEKEEWIEGEDEEL
PKNH_1324300 KN-NEVLKNLEG-MTERELEKNKNREMKREPNNT BERMOLINILMIEREN INVIDSKDKEL PEP303 FFF307.0830500 PF307.0830500 GKISVISLIKKTSYRKLTEYWKRREWKKILKKVDNENOLINLGTENVIKKNIERNNALLE PY001_0504200 ODNOAVMSYLAELPERELEKNKNEEVKKNDENDLILLGTENVIKKNEEGKINKLEGENKEVD Pv001_0504200 ODNOAVMSYLAELPERELEENKKNEEVKKNDEULALLAKERGENIKKLEGENKKEUGEKKEVED Pv0001_05015900 T EE IE-VE IPEDERELEENKKNEEVKNILDMENEOLILLUKERGENIKKLEGENKKEUGEKKELP Pm0001_05015900 R KEV-OPELPEDERELEWKKEEWKINTLDMENEOLILLUKERGENIKKLEGENIKKEEKKELE PKNH_1324300 OKNNEVLKNLEGMTERELEKKKKEEWKINTLDMENEOLILLUKERGENIKKLEKKEKKEE PV01_0504200 PVNNINKEVKKLEGMTEREELEKKKKEEWKINTLDEENDLILLAKERGENIKKLEKKEKKEE PV01_0504200 INNINKKEKKCNITINIKSTETZENEVKKEEWKINEOUGENIKTERKENKERMILD PV01_0504200 INNINKKEKKCNITINIKSTETZENEVKKEEWKINEOUGENIKTERKEPHLOPKKH PM0001_05015900 INNINKKEKKCNITINIKSTETZENEVKKEEWKINTSSTEIDNITEONIKTERKEPHLOPKKH PM0001_05015900 INNINKKEKKKNITINIKSTETZENEVKKEEWKINTSVDEKKEPHLOPKKKEL PKNH_1324300 INNINKKEKKINTINIKSTETZENEVKKEEWKINTSNDEKKEPHLOPKKKEL PEP305 INNINKKEKKINNINDINSKETZENEVKKEEWKINTS	PmUG01 05015900	-NEKEVE-OFLPEDEFELEKWKSNEWTNEMNGTENEWOLLNVOTEDEKLKWLEEKDKEL
PEP 303 PEP 303 PEP 303 PEP 303 PEP 303 PEP 303 PSD _ 0830500 PyV01_0504200 Poc6H01_00158900 P=MUG01_05015900 PKNH_1324300 PEP 304 PEP 304 PEP 304 PEP 304 PEP 304 PEP 305 PEP 305 PEP 305 PEP 305 PEP 306 PEP	PKNH 1324300	KN-NEVI, KNJ. EG-MTERELEKWKNERWKKERW/NTEREWOLLNUWTERER INWIDSKDKEL
PEP 303 PEP 303 PEP 303 PEP 303 PEP 305 PSYNETSLISSEEDEVILEOWKINEWKINEWKINKULGIINVICKINEEKKINALEE PS05 PS050 SYNETSLISSEEDEVILEOWKINEWKINEWTERVOLUNGIINUT KINEEKKINALEE POCGH01_0158900 P-CEBI-VIEDVKINEWKINEWKINEWTERVENTERVOLUNUTIEEKONVEEKKINEEKKINKUEGUNKEYD POCGH01_0515900 PKNH_1324300 PEP 307 PEP 304 PEP 305 PEP 304 PEP 305 PEP 304 PEP 305	TRAN_TSL4500	*****
PEP303 PBANKA_0701000 PF307_0830500 SYNTTSLSSDEDGEVILEDWKINENTIKWIDETEEDWQLLKULIGEIENVEKKIERINNAELE ProGH01_00158900 ProGH01_00158900 Prine_1324300 PEP304 PEP304 PEP304 PEP304 PEP304 PEP304 PEP305 PUD01_05015900 PVD1_0504200 PVD1_0504200 PVD1_0504200 PVD1_0504200 PVD1_0504200 PVD1_0504200 PVD1_0504200 PVD1_0504200 PVD1_0504200 PVD1_0504200 PVD1_0504200 PVD1_0504200 PVD1_0504200 PVD1_0504200 PVD1_0504200 PVD1_0504200 PVD1_0504200 PKNH_1324300 PEP305 PEP305 PEP305 PEP305 PEP305 PEP305 PEP305 PEP305 PEP305 PEP305 PEP305 PUD01_05015900 PVD1_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PVD01_0504200 PLEXWKTQQAHKWLWSHN_WLWAWALWAWSTYKSTY-SIDDWITEQHCMKKLEKIYNKMNL LIXAQYASLYKXITP-SIDDWITEQHCMKKLEKIYNKMNNL LIXAQYASLYKXITP-SIDDWITEQHCMKKLEKIYNKMNNL LIXAQYASLYKKITP-SIDDWITEQHCMKKLEKIYNKMNNL LIXAQYASLYKKITP-SIDDWITEQHCMKKLEKIYNKMNNL LIXAQYASLYKKITP-SIDDWITEQHCMKKLEKIYNKMNNL LIXAQYASLYKKITP-SIDDWITEQHCMKKELKNHIYNKMK PUD001_05015900 PLEXWKTQQAHKWLMSHN_WNDD_LMKKEQKHPIXSLKGDQQGIKEQLKHELKNHIYNKMKK LIXAQYASLYKKITP-SIDDWITEQHCMKKELKNHIYNKMK PUD001_05015900 PLEXWKTQQAHKWLMSHN_WNDD_LMKKEQCHPIXSLKKSUNGIKKSLEKIKSVNQIINAQMKKK LIXAVNNKMENKKMDID-MIKKEQCHPIXSLKKSUNGICKKELKSVNQIINAQMKKK LIXAVNNKMENKKMDID-MIKKEQCHPIXSLKKSUNGICKSLKESLKETKDTIYAQWKKK LIXAVNNKMENKKMDID-MIKKEQCHPIXSLKKSUNGINKKESLKESLKETKDTIYAQWKKK LIXAVNKMENKKMDID-MIKKEQCHPIXSLKKSUNGICKKESLKESLKETKDTIYAQWKKK LIXAVNKMENKKWMIDD-MIKKEQCHPIXSLKKSUNGICKSSLKESLKESLKESLKTTIYKKSKKKQTWKK PUD001_0504200 PSILSSMIIKQMIQMINKIILIKUPIXQKWKKIKIILSVLKQWYNKKIKSLKKSVNKKIKSLKKSVKKSSLKKSVKQKKKKSSLKKKWKSSLKKKKYXKKIKSSLKKKSVQKKKKKSSLKKKKKSSLKKKKKKKKKKKKKK		
PEP103 PBANKA_0701000 PF307_0830500 Pr04_0504200 PcoGH01_0515900 Pr04_050 PF307_0830500 PF207_0830500 PF307_0830500 PF307_083050		PEP 303
PBANKA_0701000 GKTSVTSLIKKTSYRKLTEYWKRENWKYLKYVDENQLALGINNV EXKHTERNNALE PF307_0830500 FYP01_0504200 ODNQAVMSYLAELP PEELEEWKNQEWKKYMEN IEBENQLALKUREEK NONIESKDKELB ProC6H01_00158900 REEIE-VEIPEDEELEEWKNQEWKKYMEN IEBENQLALKUREEK NONIESKDKELB PKNH_1324300 QKNNEVLKNLEGMTEELEKWKNEEWKNPTJDKNENWQLALUWTEEK LKHLEEKDKKELB PKNH_1324300 R-KEV-SQLPEDEERLEEWKNEEWKNPTJDKNENWQLALUWTEEK LKHLEEKDKKELB PKNH_1324300 PEP304 FY001_05015900 R-KEV-SQLPEDEERLEEWKNEEWKNPTJDKNENWQLALUWTEEKEKNNILG PF307_0830500 IWLNHUKNENKCHIDNINK-SYQCHPIKSCLKG-DQQSQIKEQLHELKNIPTYNDKKKE PVD1_0504200 NWNKMENKCHIDNINK-SCCECKIKSIS-RVDEXQNETYLKKEITYNXNNIL PF307_0830500 IWLNHUKNENKCHIDNINK-SCCECKIKSIS-RVDEXQNETYLKKEITYNXNNIL PF06GH01_00158900 FKNLDQETKWNNLDNIK-SCCECKIKSIS-RVDEXQNETYLKKEITYNXNNIL PF06GH01_00158900 FKNLDQETKWNNLDNIK-SCCECKIKSIS-RVDEXQNETYLKKEITYNXNNIL PF132_300 FEP305 FEP305 FEDSUS	PEP303	
PF307_0830500 SYNETSLLSSDEDGEVKLEDMKINENTINNDETEERQULLILMUIEGE NIKKEGINKEYD Pv001_0504200 QDNQAVMSYLAELPEERLEEMKINGEWKNYENTIERENQLULLAURIEEK (NWTESKDKELP Pm0001_05015900 TEETE-VEIPEDEERLEEWKINGEWKNYENTIERENQLULLAURIEEK (LKHIEGKOKELN PM0001_05015900 RKEV-EQELPEDEERLEEWKINEEWKNEEWKNEEWNILLAURIEEK (LKHIEGKOKELN PKNH_1324300 QKNNEVLKNLEGHTEEELEWKINEEWKNEEWKINEWNITEEWQLUNLWITEEKKINEEKKILE PEP304 FEP304 PF307_0530500 FWINTOQARKWLESNLYA-QYASLYKKITPSTEIDNVIEQWGNKKKEKIYNNNNLP PF307_0530500 FWINTOQARKWLESNLYA-QYASLYKKITPSTEIDNVIEQWGNKKKEKIYNNNNLP PF307_0530500 FWINTNNNKDEVDSVNNEQWENKTEKKENPLOPKKKKMLE PW001_0504200 NWNNKMENNKMNNDNTK-EYQCNFIKSCLKGDDQSQIKBQLHELKNFIYNNNNLP Poc6001_00158900 QWNNKMEDNWNNVDTJAD-VKCCTFROKLKDINKENKESKKKKEKTYNNNNLP PKNH_1324300 ELEKWKTQQARKWLHSN-NLVAQYASLYKKITP-STEIDNVIEQWENKLKEKTYNNNNL PF29305	PBANKA 0701000	GKISVISLIKKTSYRKLTEYWKRRRWKKYLKKVDNEWOLLNLGIENVIKKMIERNNAELE
PVP01_0504200 QDNQAVMSYLAELPEELEEMKNQEWKKYMENTEENNULLINLHITEER QNWTESKDKELE Poc6001_00158900 TEEIE-VEIPEDEELEEWKNEWKNPLOKINKENNUMLANDEEKLINIEKDKELE PMU001_05015900 RKEV-ROELPEDEELEEWKNEWKNPLOKINKENNUMLANDEEKLINIEKDKELE PKNH_1324300 QKNNEVLKNLEGMTEELEKWKNEWKNPLOKINKENNUMLANDEEKLINIEREKDKELE PEP304 FINILIKELYKNIEGMTEELEKWKNEWKNPLOKINEEROLLNUMTEER KNNIDSKDKELE PYD01_0504200 KNKTQQAHKWLHSNNLYA-QYASLYKKITPSIEIDWYTEQMKIKKEKYTNEWNIL- POGGI01_00158900 PVD01_0504200 NUMNIKENKCHHISNNLYA-QYASLYKKITPSIEIDWYTEQKKIKEKYTRUNKIKKE PVD01_0504200 NUMNIKENKCHHISNE ECKNIMENTS-R-VDESTKWNEKOWEQWMKTEGKEPMLQDFKRWL PVD01_0504200 NUMNIKENKCHHISNE ECKNIMENTS-R-VDESTKWNEKOWEQWMKTEGKEPMLQDFKRWL PVD01_0504200 QMHKMMEDNINK-EYQCKPIKSCLAGDDQSDIKEQLWELKRPIYRDWKKML PocGB01_00158900 QMHKMMEDNINN DTLND-LYKCICFKOK-LKONNEMKESLEKKSTKOTYAQWKKML PKNH_1324300 DWMNIKMENKOMIDINIK-EYQCMPIKSCLKO-DDQSDIKEQLWELKRPIYRDWKKML P2P307_0830500 EVDIWLINHMSKWYNYND IDEEYDSNVFKDSVK-WNEKGWEQWKTEGKEFMLQDFKNW PY901_0504200 ELENWNNKMENKOHID-NIK-EYQWFIKSCLKODSSIKKESLREIKDPIYRDWKKML P2P307_0830500 EVDIWLINHMSKWYNYND IDEEYDSNVFKDSVK-WNEKGWEQWKTEGKEFMLQDFKNW PY901_0504200 ELENWNKMENKOHID-NIK-EYQWFIKSCLKODSSIKKESLREIKDFIYAQWKNK PAUG01_05015900 ELENWNKMENKOMID-NIKCHID-NIKEYCENPIKSSLKGDDQSGIKEQLKELKSVHQIINAQKKKW PHUG01_05015900 ENKKKKDMEKMKINKI	PF3D7 0830500	SYNETSLLSSDEEGEVNLEDWKKNEWIKWMDETEEEWOLLKLWLEGEKNKWLEGKNKEYD
PocGH01_00158900 TBETE-VETPEDEEELEEWKNEWKNPLDRMENENULINLAMEGE LIMTEGRDREIN PRNH_1324300 QKNNEVLKNLEGMTEEELEKWKNEWKNPTNMGTENEWQLLNVQTEDEKLINLEEKDIKELE PEP304 FILE PBANKA_0701000 KWKTQQAHKWLHSNLVA-QYASLYKKTPSTEIDHVTEQMENILKERTYNRWNNL PY930_0504 KWKTQQAHKWLHSNLVA-QYASLYKKTPSTEIDHVTEQMENILKERTYNRWNNL PY930_0504 KWKTQQAHKWLHSNLVA-QYASLYKKTPSTEIDHVTEQMENILKEKSFMUQPKRKW-L PY001_0504200 NWHNIKHENKCHTDDTIK-EYQKPTKSCLKGDQSQTKEQTKHELKNFTYRDWKKKL Pw0G01_05015900 QHNKMENICHTDNTIK-EYQKPTKSCLKGDQSQTKEQTKHELKNFTYRDWKKKL PW0G01_05015900 QHNKMENKMUDDTINK-EYQKPTKSCLKGDDQQTKEQTKHELKNFTYRDWKKKL PKNH_1324300 DMMNKMENKMUDTINTK-EYQWTPTKSSLKGDDQQTKEQTKHELKNFTYRDWKKKL PEP305 FILEKWKTQQAHKWLHSNLVA-QYASLYKKTP-STEID PYD1_0504200 EYDIWLNHMNSKWTNYNKI IDEEYDSNVFKDSYK-WNEKGWEGWKTEGKEFMLQDFKNM PYD1_0504200 EYDIWLNHMNSKWTNYNKI IDEEYDSNVFKDSYK-WNEKGWEGWKTEGKEFMLQDFKNM PP307_0830500 EYDIWLNHMNSKWTNYNKI IDEEYDSNVFKDSYK-WNEKGWEGWKTEGKEFMLQDFKNM PP01_0504200 ELENWKNEDNUNND-TINK-EYQWTPTKSSLKGDDGG IKEQTKHELKNFTYNDWKKM PP01_0504200 ELENWKNMEDN-NULVYQUTYNSSLKKKTISSLKGDDGG IKEQTKHELKNFTYNDWKKM PWD601_05015900 ELENWKNMEDNUNND-TINKEYQWTYKSSLKGDDGG IKEQTKHELKNFTYNDWKKM PBANKA_07010000	PVP01 0504200	ODNOAVMSYLAELPEEELEEWKNOEWKKYMENIEEEWOLLNLWIEEEKONWIESKDKELE
PmUG01_05015900 RKEV-EQELPEDEEELEXMKSNEWINPMNGIENEWQLLNVQIEDELXMLEEKDKELE PKNH_1324300 QKNNEVLKNLEGMTEEELEXMKSNEWINPMNGIENEWQLLNVQIEDELXMLEEKDKELE PEP304 PEP304 PBANKA_0701000 KWKTQQAHKWLHSNNLYA-QYASLYKKITPSIEIDNVIEQKGMKLKEKIYMRNNLQ PYP01_0504200 KWKTQQAHKWLHSNNLYA-QYASLYKKITPSIEIDNVIEQKGMKLKEKIYMRNNLQ Pv0001_0515900 KWKRQQHETKWNALDNIK-EYQCMTKSCLKGDQSQIKEQLKHELKUPIYRDWKKWL Pw0001_05015900 KWKRQQHETKWNALDNIK-EYQCMTKSCLKGDQGQIKEQLKHELKUPIYRDWKKWL PKNH_1324300 WWNKMENKWHDIDNIK-EYQCMTKSLKGDQQQIKEQIKHELKEKIYNRWKKWL PEP305	PocGH01 00158900	TEEIE-VEIPEDEEELEEWKNKEWKNFLDKMENEWOLLNLWMEGEKLKWIEGKDKELN
PKNH_1324300 QKNNEVLKNLEGMTEEELEXMKNEEMKKPMVNIEEEMQLLNLWIEEELXNWIDSKDKELE PEP304 PEP304 PBANKA_0701000 KWKTQQAHKWLHSNNLYA-QYASLYKKITPSIEIDNVIEQKGMKLKEK IYNRWNNL- PY307_0830500 PYD01_0504200 KWKTQQAHKWLHSNNLYA-QYASLYKKITPSIEIDNVIEQKGMKLKEK IYNRWNNL- PY001_0504200 PwUG01_05015900 WWINNKENKCHHIDNINK-EYQCNFIKSCLKGDQSQIKEQLKHELKNFIYNRWNL FWNH_1324300 PEP305 ELEXWKTQQAHKWLHSN_UDLXKCFKQKDDQSQIKEQLKHELKNFIYNRWNL I	PmUG01 05015900	RKEV-EOELPEDEEELEKWKSNEWINFMNGIENEWOLLNVOIEDEKLKWLEEKDKELE
PEP304 PEP304 PEP304 PEP304 PBANKA_0701000 PF3D7_0830500 PF3D7_0830500 PF3D7_0830500 PF3D7_0830500 PF3D7_0830500 PKNLDUENENENENENENENENENENENENENENENENENENEN	PKNH 1324300	OKNNEVLKNLEGMPEERLEKWKNEEWKKPMVNIERENOLLNLWIERERKNWIDSKDKELE
PEP304 PEP304 PF3D7_0830500 FWINTQQARKWLHSNNLYA_QYASLYKKITPSTEIDWUEQMINKEKITNRWINL- PYD01_0504200 PvG6I01_00158900 FWINDWINKERNKCHIIDNINK-EYQCHTIKSCLKGDDQSQIKEQTKHELKNFIYRDWKKWL PvG6I01_0515900 GWIKINHEDNWNNVDTLND-LYKCICFKQKLKDKNEMKESIRKEIKNFIYRDWKKWL 1 * PEP305 PBANKA_0701000 PF3D7_0830500 EVDIWLNKMENKWHJDNINK-EYQWTPIKSSLKGDDQGQIKEQTKHELKNFIYRDWKKWL 1 * PEP305 PBANKA_0701000 ELEKWKTQQAHKWLHSNNLLYA_QYASLYKKITP-STEID PUP01_0504200 PVP01_0504200 PUP01_05015900 ELEKWKTQQAHKWLHSNNLD-NINK-EYQCMFIKSCLKGDQSGIKEQIKHELKNFIYRDWKKWL 1 * PEP305 PBANKA_0701000 ELEKWKTQQAHKWLHSNNLD-NINK-EYQCMFIKSCLKGDQSGIKEQIKHELKNFIYRDWKKWL 1 * PEP305 PBANKA_0701000 ELEKWKTQQAHKWLHSNNLD-NINK-EYQCMFIKSCLKGDQSGIKEQIKHELKNFIYRDWKKWL 2 * PEP305 PBANKA_0701000 ELEKWKTQQAHKWLHSN-NLYAQYASLYKKITP-STEID PBANKA_0701000 ELEKWKTQQAHKWLHSN-NLYAYSLKKTP-SKIEDDWIEQMGNKLKEKIYNRWNNL PH0G01_05015900 ELEKWKTQQAHKWLHSN-NLYAQYASLYKKITP-STEID PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PENNH_1324300 ENNIRKWVIEQWWEWKAKIISWLACDWKRWERENEKWYQWKNKYSTIKYAPNRWEYHWQ I I I PEP401 PEP401 PENNH_1324300 ENNIRKWVIEQWWEWKAKIISWLACDWKRWERENEKWYQWKNKYSTIKYAPNRWEYHWQ I I I PEP401 PEP401 PENNH_1324300 ENNIRKWVIEQWWEWKAKIISWLACDWKRWEREEKWYQWKNKYSTIKYAPNRWEYHWQ PYD01_0504200 PCGH01_00158900 PSIJNTWLYKQWIQWKNKILKWIMMKREDEWWNWERTQUWKYKYYSTIKYAPNRWEYHWQ PYD01_0504200 ESSLAWIIKQWIQWKNKILKWIMMKIKEDEPWINWERTQUWKYYKYWKYKWYKWYK I I I PEP401 PEP401 PENHCISSION PUCON PUCON P		
PEP304 PEP304 PBANKA_0701000 KWKTQQAHKWLHSNNLYA-QYASLYKKITPSTEIDWVIEQMGNKLKEKIYNRWNNLQ PF307_0830500 IWLNHMNSKWTNYNKDIDEEYDSNVPKAGYKWNEKQWEQMKKEKEKKIYNRWNNLQ PVP01_0504200 NWHNKKENKCHIDNINK-EYQCKFIKSCLKGDDQSQIKEQLKHELINFIYRDWKKML PocGH01_00158900 KWKDQNETKWNNLDNIDK-ECCKIIKENIS-RVDEKQMKEYLKSVNQIINAQWKKWL PKNH_1324300 GWNKMEDNWNVDTLND-LYKCICFKQKLKDKNEMKESLRKEIKDTIYAQWKWL PEP305 LYAQYASLYKKITP-SIEID PBANKA_0701000 ELEKWKTQQAHKWLHSN-NLAQYASLYKKITP-SIEID PYD01_0504200 EVDIWLNHMNSKWTNYNKDIDEEYDSNVFKDSYK-WNEGMEGREFMLQDFKRW Pv01_0504200 EVDIWLNHMNSKWTNYNKDIDEEYDSNVFKDSYK-WNEGMEGREFMLQDFKRW Pw0G01_05015900 ELEKWKTQQAHKWLHSN-NLAQYASLYKKITP-SIEID PW0G01_05015900 EVDIWLNHMNSKWTNYNKDIDEEYDSNVFKDSYK-WNEGMEGREFMLQDFKRW Pv01_0504200 ELENWNNKMENKCMHID-NINKEYQCWFIXSCLKADGQGIKEQIKHELKNFIYRMNNL Pw0G01_05015900 ELEWNNNKMENKCMHID-NINKEYQCWFIXSCLKADDQGGIKEQIKHELKNFIYRDWKKW ILL		Last state and stat
PEP304 GINILKEKTYNRWINL- GINILKEKTYNRWINLO PBANKA_0701000 KWKTQQAHKWLHSNNLYA-QYASLYKKITPSIEIDNVIEQKGNKLKEKTYNRWINLQ PYP01_0504200 NWHNKMENKCHNIDNIXK-EYQCMPIKSCLKGDDQSQIKEQLKHELKNPTYRWNKWL PocGH01_0015900 KWKDQMETKWNNLDNIXK-EYQCMPIKSCLKGDDQSQIKEQLKHELKNPTYRWNKWL PmUG01_05015900 GWHKMMEDNWNVDTLND-LXKCICFKQKLKDRNEMKESLKKEIKDTYAQWKKWL PMUG01_05015900 GWHKMMEDNWNVDTLND-LXKCICFKQKLKDRNEMKESLKKEIKDTYAQWKKWL PKNH_1324300 GWHKMMEDNWNVDTLND-LXKCICFKQKLKDRNEMKESLKKEIKDTYAQWKKWL PF9305 LYAQYASLYKKITP-SIEIDD FEP305 LYAQYASLYKKITP-SIEIDD PBANKA_0701000 ELEKWKTQQAHKWLHSN-NLVAQYASLYKKITP-SIEIDD PF307_0830500 EYDIWLNHMNSKWTNYNKI IDEEYDSNVFKDSYK-WNEKQWEQWMKTEGKEFMLQDFKRW PYD01_0504200 ELENWNNKMENKCHHID-N INKEYQCMFIKSCLKGDDQSQIKEQLKHELKNFIYRDWKKW Pm0G01_05015900 ELNWNKMEDNMNVD-TLNDLYKCICFFQKLKDKNEKKESLRKEIKDTYAQWKKW PMUG01_05030500 ELNWNKMEDNWNVD-TLNDLYKCICFFQKLKDKNEKKESLRKEIKDTYAQWKKW PMUG01_0504200 ELENWINKMENKNILD-N INKEYQWFFIKSSLKGDDQGQIKEQIKHELKNFIYRDWKKW PF1701_0504200 ESYLNTWLVKQWIQWKNKILBCLMNEWRREEDEWWWWKNKYNYN ILKAPTYNWWWWW PYD1_0504200 ESYLNTWLVKQWIQWKNKILBCLMNEWREEDEEWWWWKNKNYNYN ULYAPNREYHWWQ <		PEP 304
PEP304 PEP304 PBANKA_0701000 PF307_0830500 IWLNHANSKWTNYNKD IDEEYDSNVFKDSYKWNEKQWEQMMKTEGKEFNLQDFKRWI PVP01_0504200 PocGH01_00158900 PMUG01_05015900 PKNH_1324300 PEP305 PEP305 PEP305 PEP305 PEP305 PEP305 PEP305 PEP305 PELKWKTQQAHKWLHSN-LYAQYASLYKKITP-SIEID PEP305 PEP305 PELKWKTQQAHKWLHSN-LYAQYASLYKKITP-SIEID PEP305 PEP305 PELKWKTQQAHKWLHSN-NLYAQYASLYKKITP-SIEID PEP401 PocGH01_00158900 PW001_05015900 PV001_0504200 ELEKWKTQQAHKWLHSN-NLYAQYASLYKKITP-SIEID PEP401 PENNIRAKWINEDNIMNYD-TINDLYKCICFKQKLKDKHEMKESLAKEIKDTYAQWKHW PV01_0504200 ELEKWKTQQAHKWLHSN-NLYAQYASLYKKITS-SIEID PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PENNIRKWINKENKWMDID-NINKELISMLMCDWKNWQWKNKYRYITIXAQWKWW L L L L L PEP401 PEP401 PEP401 PENNIRKWVIEQWNEWKNAKIISMLDANKENENEKWYQWKNKYRYITIXAQWKWW L L L L L PEP401 PEP401 PEP401 PENNIRKWVIEQWNEWKNAKIISMLDANKKENENEKWYQWKNKYRYITIXAQWKWW L L L L L PEP401 PEP401 PEP401 PENNIKKENKWNDID-NINKENENEKWYQWKNKYRYITIXAQWKWW ELENWKNWENKWNDID-NINKENENEKWYQWKNKYRYITIXAQWKWW L L L L L PEP401 PEP401 PEP401 PENNIRKWVIEQWNEWKNAKIISMLDANKKYRYITIXSLAPHRENEKWYQWKNKYRYITIXAQWKWW L L L L L PEP401 PEP401 PENNIRKWVIEQWNEWKNAKIISMLDANKKNKILSMLANCONKKNKYRYITIXAANKKW PH01_0504200 PSSLSAWLIKQWIQWKNKILKFLMAEWKQEEDEYWNWEKTYW WLHYKRYWWW L L L L L L PEP401 PENNIKKKYYEQWNEWKNAKIISMLWKNKILKYLMYENNENEKWYQWKNKYRYITIXAPHNWEYHWQ PSSLSAWLIKQWIQWKNKILKYLMYENENEKWYQWKNKYRYITIXAPHKWWQWKWW L L L L L PEP401 PENNIKALDINAKYYYEQWNEWKNAKIISWLDANKKWYQWKNKYRYNYKKYRYYNYYYYNKYYYYKYYYYYYYYYYYYY		
PBANKA_0701000 XMKTQQAHKMLHSNNLYA-QTASLYKITPSIEIDNYTEQHENKLKEKIYINKNNLQ PF3D7_0830500 IWLNIKNENKKUTYKDIDEEYDSNYFKDSYKNNEKQWEQMIKTEGKEPNLQDFKRWL PVP01_0504200 NWNKKMENKKMEN ETQCHFIKSCLKGDDQSQIKEQIKHELKRFIYNDWKKWL PocGH01_00158900 KWKDQMETKWMNLDNIDK-ECCCHTMENIS-RVDEKQMKEYLKKSVHQIINAQWKKWL PmUG01_05015900 QWKKNMEDNWHVDTLND-LIKCICFKQKLKDKNEMKESLKKEIKDTIYAQWKHWL PKNH_1324300 DWNNKMENKWMDIDNIK-EYQWTFIKSSLKGDDQGQIKEQIKHELKNFIYNDWKWL PEP305 LYAQYASLYKKITP-SIEID PBANKA_0701000 ELEKWKTQQAHKWLHSN-NLYAQYASLYKKITP-SIEID PBANKA_0701000 EVDINLNHMSKWTNYNKIDEEYDSNVFKDSYK-WNEKQWEQWKKTEGKEFMLQDFKRW PVP01_0504200 ELENWHNKMENKCMHID-NINK-EYQCMFIKSCLKGDDQSQIKEQLKHELKNFIYRDWKKW PocGH01_00158900 ELENWKTQQAHKWLHSN-NLYAQYASLYKKITP-SIEID PwUG01_05015900 ELENWKNQQMETKWMNUD-TLNDLYKCICFKQKLKDKNEMKESLRKEIKDTIYAQWKKW PBANKA_0701000 ELENWHNKMENKWMIDD-NINK-EYQCMFIKSCLKGDDQSQIKEQLKHELKNFIYRDWKKW I I I PBCP401 IXYAPNRKYDWKWIDD-NINKEYYWYYKUJAQWKWKW PEP401 ELEDWMNNMENKWMDID-NINKEYYWYYKUJAQWKWKKEYYWYYYYYYYYYKW PBANKA_0701000 ENNIRKWDIWWYD-TLNDLYKCICFKQK-LKKNSVRQUGIKKWKWKW PF93D7_0830500 EGYLKSWLKQWIQWKNKKILECHMEWRNEEDEYWNWKEKEYWWYWKWKWW	PEP304	GIRLKERI YNRWNNL-
PF307_0830500 TWLNNENSKWTNYNKD IDBEFDSNYRDSYRDSYRDEXQWEQWENTEGKEPKLQDPRKWL PVP01_0504200 NWHNKMENKCHNIDNINK-EYQCMPIKSCLKGDDQSQIKEQIKHELKNPIYRDWKKWL PmUG01_0515900 QWHKNMEDNWHNVDTLND-LYKCICFKQKLKDKNEMKESLEKEIKDTIYAQWKHWL PRNH_1324300 QWHKNMEDNWHNVDTLND-LYKCICFKQKLKDKNEMKESLEKEIKDTIYAQWKHWL PEP305	PBANKA_0701000	KWKTQQAHKWLHSNNLYA-QYASLYKKITPSIEIDNVIEQAGNKLKEKIYNKWNNLQ
PVP01_0504200 NWRNENENCENTIONINE-EYQCMPIESCLEG-DDQSQIREQLENELENPITEDWEXEL PwcGH01_00158900 KWKDQMETKWNNUDINE-ECECHINENIS-RVDEKQMKEYLKKSVHQIINAQWEXEL PmUG01_05015900 QWRIKHEDNWNNVDTLND-LYKCICFRQKLKDINEMKESIRKSVHQIINAQWEXEL PKNH_1324300 QWRIKHEDNWNNVDTLND-LYKCICFRQKLKDINEMKESIRKEIKDTIYAQWEXEL PEP305 IIIAQYASLYKKITP-SIEID PBANKA_0701000 ELEKWKTQQAHKWLHSN-NLYAQYASLYKKITP-SIEIDNVIEQHGNKLKEKIYNRWNNL PF307_0830500 EYDIWLNHMNSKWTNYNKDIDEYDSNVFKDSYK-WNEKQWEQWRKTEGKEFMLQDFKRW Pv001_05015900 ELENWNKKMENKCHID-NIKEYQCMPIKSCLKGDQSGIKEQLKELKNFIYRDWKKW PmUG01_05015900 ELENWNNKMENKCHID-NIKEYQCMPIKSCLKGDQSGIKEQLKELKNFIYRQMKKW PmUG01_05015900 ELENWNNKMENKCHNID-NIKEYQCMPIKSCLKGDQGGIKEYLKESURGINAQWKKW PKNH_1324300 ELEQWNNKMENKWNDID-NIKEYQWTFIKSSLKGDQGGIKEQLKHELKNFIYRDWKKW PS37_0830500 EVDWKKMEDNWNVD-TLNDLYKCICFYQKLKDKNEWKESLRKEINDTYAQWKKW PKNH_1324300 ELEQWNNKMENKWNDID-NIKEYQWTFIKSSLKGDQGGIKEQLKHELKNFIYRDWKKW PS37_0830500 EGYLKSWLIKQWIQWKNKKILSWLMCDWKRNEREEDEXWSNLEDTDQIN VLHKDRKEWLRWK PY01_0504200 ESYLNTWLVKQWIQWKNKILECLMNEWRREEDEXWSNLEDTDQIN VLHKDRKEWLRWK PS17_0830500 EGYLKSWLIKQWIQWKNKILECLMNEWRREEDEXWSNLEDTDQIN VLHYKRKWQWKKW PS17_0830500 EGYLKSWLIKQWIQWKNKKILKWLIKWLIMDWKRKEDEFWTDWEXTYWW VLHYKRKWQWKWK PS16_001_00158900 ESYLNTWLVKQWIQWKNKKILECLMNEWRREEDEXWSNLEDTDQIN VLHYKRKWQWKWK <t< td=""><td>PF3D7_0830500</td><td>IWLNHMNSKWTNYNKDIDEEYDSNVFKDSYKWNEKQWEQWMKTEGKEFMLQDFKRWL</td></t<>	PF3D7_0830500	IWLNHMNSKWTNYNKDIDEEYDSNVFKDSYKWNEKQWEQWMKTEGKEFMLQDFKRWL
PecGen01_00158900 KWKDQMETKWANLDNIDK-ECECMIMENTS-RVDERQMKEYLKSVHQIINAQWKKWL PmUG01_05015900 QWNKMMEDNWNVDTLND-LYKCICFKQKLKDKNEMKESLRKEIKDTIYAQWKKWL PKNH_1324300 DWNKMENKWNDIDNIK-EYQWTPIKSSLKGDDQGQIKEQTKKEKINFIYAQWKKWL PEP305	PVP01_0504200	NWRNEMENECHHIDNINE-EYQCHFIESCLEGDDQSQIEEQLEHELENFIYRDWEEWL
PmUG01_05015900 QWMKNMEDNWNVDTLND-LYKCICFRQKLKDKNEHKESLEKEIKDTIYAQWKHWL PKNH_1324300 DWMKKMEDNWNVDTLND-LYKCICFRQKLKDKNEHKESLEKEIKDTIYAQWKHWL I i PEP305 I PBANKA_0701000 ELEKWKTQQAHKWLHSN-NLYAQYASLYKKITP-SIEID PF005 ELEKWKTQQAHKWLHSN-NLYAQYASLYKKITP-SIEIDNVIEQMGNKLKEKIYNRWNNL PV010504200 EVDIWLNHMNSKWTNYNKDIDESDSNVFXb5YK-WNEKQWEQMKTEGKEFMLQDFKRW Pw0601_0505900 ELEKWKTQQAHKWLHSN-NLYAQYASLYKKITP-SIEIDNVIEQMGNKLKEKIYNRWNNL PmUG01_05015900 ELEKWKTQQAHKWLHSN-NLYAQYASLYKKITP-SIEIDNVIEQMGNKLKEKIYNRWNNL PmUG01_05015900 ELEKWKTQQAHKWLHOL-NINKEYQCMFIKSCLKGDDQSQIKEQIKHELKNFIYRDWKKW PKNH_1324300 ELEQWMKNMENKMMDID-NINKEYQWTFIKSSLKGDDQGQIKEQIKHELKNFIYRDWKKW PEP401 IXYAPNRKEYHVWQ PBANKA_0701000 ENNIRKWVIEQWNEWKNAKIISWLACDWKRNENEKWVQWKNKYRYIKYAPIKYAPNRNEYHVWQ PS3D7_0830500 EGYLKSWLIKQWIQWKNNKILECLMNEWRREEDEXWSNLEDTDQII VLNHKDRKEWLWK PY01_0504200 ESYLNTWLVKQWIQWKNNKILECLMNEWRREEDEXWSNLEDTDQII VLNHKDRKEWLWK PocGH01_00158900 ESYLNTWLVKQWIQWKNNKILECLMNEWRREEDEXWSNLEDTDQII VLNHKDRKEWLWK PocGH01_00158900 ESYLNTWLVKQWIQWKNNKILECLMNEWRREEDEXWNNWEKTYW WLAUTKRWKWK PocGH01_00158900 ESYLNTWLVKQWIQWKNNKILECLMNEWRREEDEZWNDWEKTYW WLAUTKRWQUWK <t< td=""><td>PocGH01_00158900</td><td>KWKDQMETKWHNLDNIDK-ECECHIMENIS-RVDEKQMKEYLKKSVHQIINAQWKKWL</td></t<>	PocGH01_00158900	KWKDQMETKWHNLDNIDK-ECECHIMENIS-RVDEKQMKEYLKKSVHQIINAQWKKWL
PRNH_1324300 DWMNKMENKWMDIDNINK-EYQWTFIKSSLKGDDQGQIKEQIKHELKNFIYRDWRKWL i * PEP305 PEP307_0830500 PF3D7_0830500 ELEKWKTQQAHKWLHSN-NLYAQYASLYKKITP-SIEID-VIEQMGNKLKEKIYNRWNNL PVP01_0504200 ELENWKNQMETKWMLD-NINK-YQCMFIKSCLKGDDQSGIKEQLKHELKNFIYRDWRKW PocGH01_00158900 ELENWNNKMENKCMHID-NINKEYQCMFIKSCLKGDDQSGIKEQLKHELKNFIYRDWKKW PmUG01_05015900 ELENWNNKMENKCMHID-NINKEYQCMFIKSCLKGDDQSGIKEQLKHELKNFIYRDWKKW PKNH_1324300 ELEDWMNKMENKMEDNWMNVD-TLNDLYKCICFKQKLKDXNEMKESLRKEIKDTIYAQWKHW PEP401 I PEP401 IXYAPNRNEYHVWQ PSD7_0830500 EGYLKSWLIKQWIQWKNKILISWLMCDWRRNENEKWVQWKNKYRYN IKYAPNRNEYHVWQ PKNH_1324300 ENNIRKWVIEQWNEWKNAKIISWLMCDWRRNENEKWVQWKNKYRYN IKYAPNRNEYHVWQ PSD7_0830500 EGYLKSWLIKQWIQWKNNKILECLMNEWREEDEWWNWEKTXTW, WLHFYKRRWQTWK PVP01_0504200 ESYLNTWLVKQWIQWKNNKILKFLAMEWRREEDEWWNWEKTXTW, WLHFYKRRWQTWK PocGH01_00158900 ESYLNTWLVKQWIQWKNNKILKFLAMEWREEDEFWNDWEKTXTW, WLHFYKRRWQTWK PocGH01_05015900 ESYLNTWLVKQWIQWKNNKILKFLAMEWRREEDEFWNDWEKTXTW, WLHFYKRRWQTWK Pru001_05015900 ESYLNTWLVKQWIQWKNNKILKYLIKWLMIDWRKKEDEFWTDWEKTTYM WLHFYKRRWQTWK PKNH_1324300 ESYLNTWLVKQWIQWKNNKILKYLWKMEKEDEFWTDWEKTTYM WLHFYKRRWQTWK	PmUG01_05015900	QWHKMMEDNWHNVDTLND-LYKCICFKQKLKDKNEMKESLRKEIKDTIYAQWKHWL
PEP305 PBANKA_0701000 PF3D7_0830500 PV01_0504200 PocGH01_00158900 PMUG01_05015900 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401 PEP401	PKNH_1324300	DWHNKMENKWHDIDNINK-EYQWTFIKSSLKGDDQGQIKEQIKHELKNFIYRDWKKWL
PEP305 PEP305 PBANKA_0701000 ELEKWKTQQAHKWLHSN-NLYAQYASLYKKITP-SIEID PYD01_0504200 EYD IWLNHMNSKWTNYNKI IDEEYDSNYFXDSYK-WNEK WEQWMKTEGKEFMLQDFXRW PocGH01_00158900 ELENWHNKMENKCMHID-NINKEYQCMFIXSCLKGDDQSQIKEQLKHELKNFIYRDWKKW PmUG01_05015900 ELENWHNKMENKCMHID-NINKEYQCMFIXSCLKGDDQSQIKEQLKHELKNFIYRDWKKW PmUG01_05015900 ELENWHNKMENKCMHID-NINKEYQCMFIXSCLKGDDQSQIKEQLKHELKNFIYRDWKKW PKNH_1324300 ELEQWMKIMEDNWNVD-TLNDLYKCICFXQKLKDXNEMKESLKEIKDTIYAQWKKW PEP401 IXYAPNRNEYHVWQ PBANKA_0701000 ENNIRKWVIEQWNEWKNAKIISWLMCDWKRNENEKWVQWKNKYRYI IXYAPNRNEYHVWQ PF3D7_0830500 EGYLKSWLIKQWIQWKNNKILECLMNEWREEDEKWSNLEDTDQI VLNHKDRKEWLRWK PVP01_0504200 ESYLMTWLVKQWIQWKNNKILKPLMAEWRQEEDEYWNDWEKTXTW WLHYYRRKWQWK PvcGh01_00158900 ESSLSAMLIKQWIQWKNNKILKPLMAEWRQEEDEYWNDWEKTXTW WLHYYRRKWQWK PwuG01_05015900 ESYLMTWLVKQWIQWKNNKILKYLWAKNKKQEDEYWNNWEKTHYM WIHPWKKQKWEIWK PKNH_1324300 ESYLMTWLVKQWIQWKNNKILKYLWKBEDEYWNNWEKTHYM WIHPWKKQKWEIWK		1 *
PEP305 PEP305 PBANKA_0701000 ELEKWKTQQAHKWLHSN-NLYAQYASLYKKITP-SIEID PF3D7_0830500 EYDIWLNHMNSKWTNYNKI IDEEYDSNVFKDSYK-WNEKOWEQWMKTEGREFMLQDFKRW PVP01_0504200 ELENWNNKMENKCMHID-NINKEYQCMFIKSCLKGDDQSQIKEQLKHELKNFIYRDWKKW PocGH01_00158900 ELENWNNKMENKCMHID-NINKEYQCMFIKSCLKGDDQSQIKEQLKHELKNFIYRDWKKW PmUG01_05015900 ELEQWMKNMEDNWNVD-TLNDLYKCICFKQKLKDKNEMKESLRKEIKDTIYAQWKHW PKNH_1324300 ELEQWMKNMENKWDID-NINKEYQWTFIKSSLKGDDQGQIKEQLKHELKNFIYRDWKKW PEP401 IXYAPNRNEYHVWQ PBANKA_0701000 ENNIRKWVIEQWNEWKNAKIISWLMCDWKRNENEKWVQWKNKYRYHKYAPNRNEYHVWQ PF3D7_0830500 EGYLKSWLIKQWIQWKNNKILECLMNEWRREEDEKWSNLEDTDQIRVLNHKDRKEWLRWK PVD01_0504200 ESYLNTWLVKQWIQWKNNKILKPLAAEWKQEEDEYWNDWEKTXTW WLHPYKRRKWQIWK PocGH01_00158900 ESYLNTWLVKQWIQWKNNKILKPLAAEWKQEEDEYWNNWEKTQYH WLQITKRNKWQIWK PmUG01_05015900 ESYLNTWLVKQWIQWKNNKILKPLAAEWKQEEDEYWNNWEKTQYH WLQITKRNKWQIWK PMUG01_05015900 ESYLNTWLVKQWIQWKNNKILKYLTVEWKHEEDEYWNNWEKTETWRWLNFSKRRNWQTWK PKNH_1324300 ESYLNTWLVKQWIQWKNNKILKYLTVEWKHEEDEYWNNWEKTETWRWLNFSKRRNWQTWK		
PEP305 LYAQYASLYKKITP-SIEID PBANKA_0701000 ELEKWKTQQAHKWLHSN-NLYAQYASLYKKITP-SIEIDNVIEQMGNXLKEKIYNRWNNL PF3D7_0830500 EYD IWLNHMNSKWTNYNKD IDEEYDSNVFXDSYK-WNEK WEQWMX TEGREFMLQDFXRW PVP01_0504200 ELENWNNKMENKCMHID-NINKEYQCMFIKSCLKGDDQSGIKEQLKHELKNFIYRDWKKW PocGH01_00158900 ELNKWKDQMETKWMNLD-NIDKECECMIMENIS-RVDEKGMKEYLKKSVHQIINAQWKKW PmUG01_05015900 ELEQWMKMMEDNWMNVD-TLNDLYKCICFKQKLKDKNEMKESLRKEIKDTIYAQWKHW PKNH_1324300 ELEDWNNKMENKMDID-NINKEYQWTFIKSSLKGDDQGGIKEQIKHELKNFIYRDWKKW PEP401 I PBANKA_0701000 ENNIRKWVIEQWNEWKNAKIISWLMCDWKRNENEKWVQWKNKYRYIIKYAPNRNEYHVWQ PF3D7_0830500 EGYLKSWLIKQWIQWKNNKILECLMNEWRREEDEXWSNLEDTDQIIVLNHKDRKEWKRWK PVD01_0504200 ESYLNTWLVXQWIQWKNNKILKFILKWLMIDWKREEDEYWNDWEKTYW WLPYKRRKWQTWK PocGH01_00158900 ESSLSAWLIKQWIQWKNNKILKYLMMIDWKREEDEYWNDWEKTYW WLPYKRRKWQTWK PwUG01_05015900 ETYMNSLVVRQUIWKNNKILKYLWWIWKNKWILKFILKWLMIDWKREEDEYWNWEKTYM WLHFYKRRKWQTWK PMUG01_05015900 ETYMNSLVVRQUIWKNNKILKYLTVEWKHEEDEYWNNWEKTYM WIHPWKKQKNEIWK PKNH_1324300 ESYLNTWLVKQWIQWKNNKILKYLTVEWKHEEDEYWNNWEKTYM WLHPSKRRNQTWK		PEP 305
PBANKA_0701000 ELEXWKTQQAHKWLHSN-NLYAQYASLYKKITP-SIEIDNVIEQMGNXLKEKIYNRWNNL PF3D7_0830500 EYDIWLNHMNSKWTNYNKDIDEEYDSNVFKDSYK-WNEKQWEQWMKTEGREFMLQDFXRW Pvv01_0504200 ELENWNNKMENKCMHID-NINKEYQCMFIKSCLKGDDQSQIKEQLKHELKNFIYRDWKKW PocGH01_00158900 ELNWWNKMENKCMHID-NINKEYQCMFIKSCLKGDDQSQIKEQLKHELKNFIYRDWKKW PmUG01_05015900 ELNWWNKMENKCMHID-NINKEYQCMFIKSCLKGDDQSQIKEQLKHELKNFIYRDWKKW PKNH_1324300 ELEQWMKMMEDNWMNVD-TLNDLYKCICFKQKLKDKNEMKESLRKEIKDTIYAQWKHW PEP401 i PBANKA_0701000 ENNIRKWVIEQWNEWKNAKIISWLMCDWKRNENEKWVQWKNKYRYIKYAPNRNEYHVWQ PF3D7_0830500 EGYLKSWLIKQWIQWKNNKILECLMNEWRREDEEXWSNLEDTDQISVLNHKDRKEWLRWK PV01_0504200 ESYLNTWLVXQWIQWKNNKILKFLMMEWRREDEEXWSNLEDTDQISVLNHKDRKEWLRWK Pv0G01_05015900 ESSLSAWLIKQWIQWKNNKILKFLMMEWRREDEEXWSNLEDTDQISVLNHKDRKEWLRWK PmUG01_05015900 ESYLNTWLVXQWIQWKNNKILKYLWMIDWKRKEDEPYWNWEKTYM WLPYKRRKWQIWK PKNH_1324300 ESYLNTWLVKQWIQWKNNKILKYLVEWKHEEDEYWNNWEKTYM WLPYKRRKWQIWK	PEP305	LYACYASLYKKITP-SIRID
PF3D7_0830500 EYD IWLNHMNSKWTNYNKD IDEEYDSNVFXDSYK-WNEKOWEQWMKTEGREFMLQDFXRW PV001_0504200 ELENWNNKMENKCMHID-NINKEYQCMFIKSCLKGDDQSGIKEQLKHELKNFIYRDWKKW PocGH01_00158900 ELNWKNKMENKCMHID-NINKEYQCMFIKSCLKGDDQSGIKEQLKHELKNFIYRDWKKW PmUG01_05015900 ELEQWMKNMEDNWMNVD-TLNDLYKCICFKQKLKDKNEMKESLRKEIKDTIYAQWKKW PKNH_1324300 ELEQWMKNMEDNWMNVD-TLNDLYKCICFKQKLKDKNEMKESLRKEIKDTIYAQWKKW PEP401 i PBANKA_0701000 ENNIRKWVIEQWNEWKNAKIISWLMCDWKRNENEKWVQWKNKYRYHW PVD1_0504200 EYLKWLIKQWIQWKNNKILECLMNEWRREDEKWSNLEDTDQIRVLNHKDRKEWLRWK PVP01_0504200 ESYLNTWLVKQWIQWKNNKILKFILAEWKQEEDEYWNDWEKTYW WLQITKRRKWQTWK PvD01_05015900 ESSLSAWLIKQWIQWKNNKILKFILAEWKQEEDEYWNDWEKTYW WLQITKRRKWQTWK PmUG01_05015900 EYYNNSLVVKQWIHWKNSKILQWLQWKNNKILKFILAEWKQEEDEYWNNWEKTHYM WLPYKRRKWQTWK PKNH_1324300 ESYLNTWLVKQWIQWKNNKIIKYLTYEWKHEEDEYWNNWEKTHYM WLPSKRRNWQTWK	PBANKA 0701000	ELEKWETOOAHKWEHSN-NLYAOYASLYKETTP-STETDNUT ROMGNYLKEETYNRWNNL
PVP01_0504200 ELENWINKMENKCMHID-NINKEYQCMPIKSCLKGDQSGIKEQLKHELKNFIYRDWKKW PocGH01_00158900 ELENWINKMENKCMHID-NINKEYQCMPIKSCLKGDQSGIKEQLKHELKNFIYRDWKKW PmUG01_05015900 ELEQWIKKMEDNWNVD-TLNDLYKCICFKQKLKDKNEMKESLRKEIKDTIYAQWKKW PKNH_1324300 ELEDWINKMENKWIDD-NINKEYQWTPIKSSLKGDDQGGIKEQIKHELKNFIYRDWKKW PEP401 i PBANKA_0701000 ENNIRKWVIEQWNEWKNAKIISWLMCDWKRNENEKWVQWKNKYRYHIXAPNRNEYHVWQ PJD7_0830500 EGYLKSWLIKQWIQWKNNKILECLMNEWREEDEKWSNLEDTDQIRVLNHKDRKEWLRWK PVP01_0504200 ESYLNTWLVKQWIQWKNNKILKFLMAEWRQEEDEYWNDWEKTKTW WLHFYKRRKWQTWK PwG01_05015900 ESSLSAWLIKQWIQWKNNKILKFLMAEWRQEEDEYWNDWEKTTYW WLHFYKRRKWQTWK PmUG01_05015900 ETYMNSLVVRQWIQWKNNKILKYLTVEWKHEEDEYWNNWEKTHYM WIHPWKKQKWEIWK PKNH_1324300 ESYLNTWLVKQWIQWKNNKILKYLTVEWKHEEDEYWNNWEKTETWWLNFSKRRNWQTWK	PE307 0830500	EVD TWI NHMNS KWTNYNKO T DREYDSNYFKDSYK-WNEKOWROWKTEGKEPMI ODFKRW
PocGH01_00158900 ELNXWKDQMETKWMNLD-NIDKECECMINENIS-RVDEKGMKEYLKKSVHQIINAQWKKW PmUG01_05015900 ELEQWMKMMEDNWMNVD-TLNDLYKCICFKQKLKDKNEMKESLRKEIKDTIYAQWKKW PKNH_1324300 ELEQWMKMMEDNWMNVD-TLNDLYKCICFKQKLKDKNEMKESLRKEIKDTIYAQWKKW PEP401 i <iii< td=""> PBANKA_0701000 ENNIRKWVIEQWNEWKNAKIISWLMCDWKRNENEKWVQWKNKYRYHIKYAPNRNEYHVWQ PF3D7_0830500 EGYLKSWLIKQWIQWKNNKILECLMNEWRREEDEKWSNLEDTDQIRVLNHKDRKEWLRWK PVP01_0504200 ESYLNTWLVKQWIQWKNNKILKFLMAEWKQEEDEYWNDWEKTKTW WLHFYKRRKWQTWK PocGH01_00158900 ESSLSANLIKQWIQWKNKKILKWLMIDWKRKEDEFWTDWEKTQYM WLQITKRNKWQIWK PmUG01_05015900 ETYMNSLVVKQWIHWKNSKILQWLMSDWKRQEDEYWNWEKTHYM WIHPWKKQKWEIWK PKNH_1324300 ESYLNTWLVKQWIQWKNNKIIKYLTYEWKHEEDEYWNWEKTETWWLNFSKRRNWQTWK</iii<>	PVP01 0504200	FLENWINKMENKCHHTD-NTNKEVOCHPTKSCLKGDDOSQTKEOLKHELKNPTYPDWKKW
PmUG01_05015900 ELEQWMKMMEDNWMNVD-TLNDLYKCICFKQKLKDKNEMKESLRKEIKDTIYAQWKHW PKNH_1324300 ELEQWMKMMEDNWMNVD-TLNDLYKCICFKQKLKDKNEMKESLRKEIKDTIYAQWKHW PEP401 i <iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii< td=""><td>PocGH01 00158900</td><td>PLAKWEDOMPTKUMALD-NTOKECECHTMENTS-EVOPECMKEVIJKESVBOTTAAOWKKW</td></iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii<>	PocGH01 00158900	PLAKWEDOMPTKUMALD-NTOKECECHTMENTS-EVOPECMKEVIJKESVBOTTAAOWKKW
PKNH_1324300 ELEDWMNKMENKWMDID-NINKEYQWTFIKSSLKGDDQGQIKEQIKHELKNFIYRDWKKW PEP401 Imperation of the second	PmIIG01 05015900	FLEOLINK MAEDNIMNUD-ST.NDI.YKCTCFKOKI.KDYNTMKESI.RKETYDTI VAOHKAN
PEP401 PBANKA_0701000 PF3D7_0830500 PF3D7_0830500 PVP01_0504200 PvcGH01_00158900 PmUG01_05015900 PmUG01_05015900 PtMNSLVVKQWIQWKNNKILKVLUVKQWIQWKNNKILKVLTVEWKHEEDEYWNWEKTTYM WLHPVKKQKWEIWK PKNH_1324300 PKNH_14X	PKNH 1324300	PLEDUM FUNDING DU ANDRE SUPERIO SUPERIO SUPERIO SUPERIO SUPERIO DE LA CONTRA DE L
PEP401 PBANKA_0701000 ENNIRKWVIEQWNEWKNAKIISWLMCDWKRNENEKWVQWKNKYRYHIXYAPNRNEYHVWQ PF307_0830500 EGYLKSWLIKQWIQWKNNKILECLMNEWRREEDEKWSNLEDTDQIFVLNHKDRKEWLRWK PVP01_0504200 ESYLNTWLVKQWIQWKNNKILKPLMAEWKQEDEYWNDWEKTKTW WLHFYKRRKWQTWK PocGH01_00158900 ESSLSAWLIKQWIQWKNTKILKWLMIDWKRKEDEFWTDWEKTQYM WLQITKRNKWQIWK PmUG01_05015900 ETYMNSLVVKQWIHWKNSKILQWLMSDWKRQEDEYWNWEKTHYM WIHPWKKQKWEIWK PKNH_1324300 ESYLNTWLVKQWIQWKNNKIIKYLTVEWKHEEDEYWNNWEKTETWGWLNFSKRRNWQTWK	FRAN_ISE4500	
PEP401 IKYAPNRNEYHVWQ PBANKA_0701000 ENNIRKWVIEQWNEWKNAKIISWLMCDWKRNENEKWVQWKNKYRYHIKYAPNRNEYHVWQ PF3D7_0830500 EGYLKSWLIKQWIQWKNNKILECLMNEWRREEDEKWSNLEDTDQIRVLNHKDRKEWLRWK PVP01_0504200 ESYLNTWLVKQWIQWKNNKILKPLMAEWKQEEDEYWNDWENTTWIWLHFYRRKWQTWK PocGH01_00158900 ESSLSAWLIKQWIQWKNNKILKWLMIDWKRKEDEFWTDWEKTQYM WLQITKRNKWQIWK PmUG01_05015900 ETYMNSLVVKQWIHWKNSKILQWLMSDWKRQEDEYWNWEKTHYM WIHPWKKQKWEIWK PKNH_1324300 ESYLNTWLVKQWIQWKNNKIIKYLTYEWKHEEDEYWNNWEKTETWIWLNFSKRRNWQTWK		Li
PEP401 IKYAPNRNEYHVWQ PBANKA_0701000 ENNIRKWVIEQWNEWKNAKIISWLMCDWKRNENEKWVQWKNKYRYHIKYAPNRNEYHVWQ PF3D7_0830500 EGYLKSWLIKQWIQWKNNKILECLMNEWRREEDEKWSNLEDTDQIRVLNHKDRKEWLRWK PVP01_0504200 ESYLNTWLVKQWIQWKNNKILKFLMAEWRQEEDEYWNDWEKTKTWWLHFYKRRKWQTWK PocGH01_00158900 ESSLSAWLIKQWIQWKNTKILKWLMIDWKRKEDEFWTDWEKTTYWKLHFYKRRKWQTWK PmUG01_05015900 ETYMNSLVVRQWIHWKNSKILQWLMSDWKRQEDEYWNNWEKTHYMKWIHFWKKQKWEIWK PKNH_1324300 ESYLNTWLVKQWIQWKNNKIIKYLTYEWKHEEDEYWNNWEKTETWWLNFSKRRNWQTWK		BED 401
PEP401 IXYAPNRNEYHVWQ PBANKA_0701000 ENNIRKWVIEQWNEWKNAKIISWLMCDWKRNENEKWVQWKNKYRYHIKYAPNRNEYHVWQ PF3D7_0830500 EGYLKSWLIKQWIQWKNNKILECLMNEWRREEDEKWSNLEDTDQIRVLNHKDRKEWLRWK PVP01_0504200 ESYLNTWLVKQWIQWKNNKILKFLMAEWRQEEDEYWNDWEKTKTWSWLHPYKRRKWQTWK PocGH01_00158900 ESSLSAWLIKQWIQWKNTKILKWLMIDWKRKEDEFWTDWEKTQYMSWLQITKRNKWQIWK PmUG01_05015900 ETYMNSLVVKQWIHWKNSKILQWLMSDWKRQEDEYWNWEKTHYMKWIHPWKKQKWEIWK PKNH_1324300 ESYLNTWLVKQWIQWKNNKIIKYLTVEWKHEEDEYWNNWEKTETWKWLNPSKRRNWQTWK		PEP 401
PBANKA_0701000 ENNIRKWVIEQWNEWKNAKIISWLMCDWKRNENEKWVQWKNKYRYHIKYAPNRNEYHVWQ PF3D7_0830500 EGYLKSWLIKQWIQWKNNKILECLMNEWRREEDEKWSNLEDTDQIRVLNHKDRKEWLRWK PVP01_0504200 ESYLNTWLVKQWIQWKNNKILKFLMAEWRQEEDEYWNDWEKTKTWSWLHPYKRRKWQTWK PocGH01_00158900 ESSLSAWLIKQWIQWKNNKILKWLMIDWKRKEDEFWTDWEKTQYMSWLQITKRNKWQIWK PmUG01_05015900 ETYMNSLVVKQWIHWKNSKILQWLMSDWKRQEDEYWNNWEKTHYMKWIHPWKKQKWEIWK PKNH_1324300 ESYLNTWLVKQWIQWKNNKIIKYLTYEWKHEEDEYWNNWEKTETWKWLNPSKRRNWQTWK	PEP401	IKYAPNENEYHVWQ
PF3D7_0830500 EGYLKSWLIKQWIQWKNNKILECLMNEWRREEDEKWSNLEDTDQIRVLNHKDRKEWLRWK PVP01_0504200 ESYLNTWLVKQWIQWKNNKILKFLMAEWKQEEDEYWNDWEKTKTWSWLHPYKRRKWQTWK PocGH01_00158900 ESSLSAWLIKQWIQWKNTKILKWLMIDWKRKEDEFWTDWEKTQYMSWLQITKRNKWQIWK PmUG01_05015900 ETYMNSLVVKQWIHWKNSKILQWLMSDWKRQEDEYWNNWEKTHYMKWIHPWKKQKWEIWK PKNH_1324300 ESYLNTWLVKQWIQWKNNKIIKYLTYEWKHEEDEYWNNWEKTETWKWLNPSKRRNWQTWK	PBANKA_0701000	ENNIRKWVIEQWNEWKNAKIISWLMCDWKRNENEKWVQWKNKYRYHIKYAPNRNEYHVWQ
PVP01_0504200 ESYLNTWLVKQWIQWKNNKILKPLMAEWKQEEDEYWNDWEKTKTWKWLHPYKRRKWQTWK PocGH01_00158900 ESSLSAWLIKQWIQWKNTKILKWLMIDWKRKEDEPWTDWEKTQYMKWLQITKRNKWQIWK PmUG01_05015900 ETYMNSLVVKQWIHWKNSKILQWLMSDWKRQEDEYWINWEKTHYMKWIHPWKKQKWEIWK PKNH_1324300 ESYLNTWLVKQWIQWKNNKIIKYLTYEWKHEEDEYWNNWEKTETWKWLNPSKRRNWQTWK	PF3D7_0830500	EGYLKSWLIKQWIQWKNMKILECLMNEWRREEDEKWSNLEDTDQIRVLNHKDRKEWLRWK
PocGH01_00158900 ESSLSAWLIKQWIQWKNTKILKWLMIDWKRKEDEPWTDWEKTQYMEWLQITKRNKWQIWK PmUG01_05015900 ETYMNSLVVKQWIHWKNSKILQWLMSDWKRQEDEYWINWEKTHYMEWIHPWKKQKWEIWK PKNH_1324300 ESYLNTWLVKQWIQWKNNKIIKYLTVEWKHEEDEYWNNWEKTETWEWLNPSKRRNWQTWK	PVP01_0504200	ESYLNTWLVKQWIQWKNNKILKFLMAEWKQEEDEYWNDWEKTKTWKWLHFYKRRKWQTWK
PmUG01_05015900 ETYMNSLVVKQWIHWKNSKILQWLMSDWKRQEDEYWINWEKTHYMEWIHPWKKQKWEIWK PKNH_1324300 ESYLNTWLVKQWIQWKNNKIIKYLTVEWKHEEDEYWNNWEKTETWEWLNPSKRRNWQTWK	PocGH01_00158900	ESSLSAWLIKQWIQWKNTKILKWLMIDWKRKEDEFWTDWEKTQYMEWLQITKRNKWQIWK
PKNH_1324300 ESYLNTWLVKQWIQWKNNKIIKYLTVEWKHEEDEYWNNWEKTETWKWLNPSKRRNWQTWK	PmUG01_05015900	ETYMNSLVVKQWIHWKNSKILQWLMSDWKRQEDEYWINWEKTHYMKWIHPWKKQKWEIWK
	PKNH_1324300	ESYLNTWLVKQWIQWKNNKIIKYLTVEWKHEEDEYWNNWEKTETWKWLNFSKRRNWQTWK
1* 11.1.		.1.11 *1

FIGURE 5 T-epitope conservation among human parasites. Multiple sequence alignment of SLTRiP immunodominant peptides (302, 303, 304, 305, and 401) with SLTRiP orthologs in human *Plasmodium* species: *P. falciparum* (PF3D7_0830500), *P. vivax* (PVP01_0504200), *P. ovale* (PocGH01_00158900), *P. malariae* (PmUG01_05015900), *P. knowlesi* (PKNH_1324300). The conservation of amino acid tryptophan (W), along with other hydrophobic amino acids (V, I, L, F) and charged amino acids (K, R, E, D) is majorly observed in protective peptides 302 and 303. "*" fully conserved residue; ":" conservation between strongly similar residues; "." conservation between weakly similar residues

there exists a general notion that multiple antigens, either through whole-parasite inclusion of many proteins or polypeptides are required for an effective malaria vaccine.²⁴ However, protein fragments are unlikely to be effective unless they include critical epitopes recognized by protective immune cells. An approach for development of effective vaccine against malaria includes identification of protein regions that can generate protective immune responses.²⁵ Epitope mapping has multiple advantages for vaccine development as they represent antigenic regions of the protein and consequently nonprotective parts can be removed.^{26,27} Epitopes from different alleles can also be collected for the formation of a peptide library that will be recognized by majority of immune populations. In addition, using mouse model, the peptide-specific protective efficacy can be characterized by mice immunization.

59

SLTRiP protein was of particular interest as it was able to demonstrate protective efficacy in mice model.²² The in silico analysis showed that protein has B- and T-cell epitopes. An epitope is frequently used for an immunodominant peptide. Our previous results demonstrate that the high titer antibodies generated were nonprotective. Therefore, we proceeded to identify T-cell epitopes in SLTRiP. For this, we synthesized multiple nonoverlapping fragments from SLTRiP protein to identify particular protein fragments that are protective. Identification of the T-cell epitopes of the 413 amino acid long SLTRiP protein would have been a laborious process by conventional methods, as it involves synthesizing short overlapping oligopeptides of the full-length protein. We, therefore, synthesized multiple fragments of our gene to identify protective regions. The in silico studies have shown that the epitopes for T-cells are generally present in hydrophobic regions of protein while hydrophilic regions score best for B-cell epitopes.²⁷ Using this information, bioinformatics approach was employed to identify hydrophobic regions of the protein using Parker hydrophilicity prediction to identify hydrophobic regions in protein. By generating recombinant subfragments of the protein SLTRiP, we observed that the immunodominant T-cell epitopes of the protein are located between amino acids 155 and 355, which forms the protective SLTRiP C3 and SLTRiP C4 fragments of protein SLTRiP. These two fragments demonstrated major protection in C57BL/6 mice, which are conventionally difficult to protect than other mice strains.²⁸ Mice immunized with SLTRiP C5 showed partial protection while SLTRiP C2 showed no protection. SLTRiP C2 contains mostly hydrophilic regions of protein as seen by Parker hydrophilicity prediction. The nonprotective results of C2 correspond with our earlier hypothesis stating that most of protection relies on T-cell epitopes.

To study the protective epitopes, first of all T-epitopes from the protective fragment were predicted using computer algorithm-based predictions. These programs predict the potential of a peptide to bind to a particular MHC class I molecule using MHC peptide binding. Number of peptides required to be synthesized could be significantly reduced by employing such methods. The program prediction is based on the affinity of the peptides and T-cell receptor but it cannot predict the processing, proteolysis, expression, or availability of the peptide on the cell surface. Some of the peptides predicted do not induce a T-cell proliferation response and the peptides need to be checked in vitro for their ability to induce immune responses. Previous research has shown that protective immune responses after immunization are dependent on T cells secreting IFN- γ .²⁹ Therefore, we identified and validated T-cell epitopes of the SLTRiP protein immunodominant for IFN-y secretion; however, these may be only a subset of the total T-cell repertoire that exists in vivo.

Recently, the whole-parasite vaccination approach has also been revived, despite challenges in sporozoite production. A number of blood-stage and transmission-blocking candidates are also being tested with different adjuvant formulation and delivery routes for malaria vaccine development; however, many groups believe that evaluation and identification of subunit vaccine candidates, acting synergistically to induce protective responses, can add to the efforts targeting multiple stages of parasite's life cycle. The subunit vaccines undergoing clinical assessment currently are PfCSP and PfTRAP. Studies in mice have shown that immunization using viral vectors expressing ME-TRAP (multiepitope TRAP) induces protective immune responses in the liver.³⁰ Although SLTRiP peptides do not provide sterile protection preclinically, we demonstrate the significantly high level of protective efficacy of these peptides by immunization and challenge experiments. In addition, sequence conservation analysis with human Plasmodium species revealed that these peptides were conserved, in fact, some amino acid residues, particularly positionally constrained tryptophan showed 100% identity in most of these strains. Therefore, these peptides or its equivalent from other Plasmodium species could impart protection against malaria in other hosts too. While antigens like CSP provide greater levels of protection clinically, we demonstrate the value of including these peptides in a multicomponent subunit second-generation vaccines for the development of a subunit vaccine with improved protective efficacy.

ACKNOWLEDGMENTS

We thank Mr. Vivek Kumar Pandey for his technical assistance in mosquito breeding. This study received financial support from NII core grant from Department of Biotechnology (DBT), Government of India, sanctioned to APS. AQ received financial support (JRF/SRF fellowship) from DBT through NII. This study was partly supported by a DST grant (EMR/2015/001546), Government of India sanctioned to APS.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

DATA AVAILABILITY STATEMENT

All data are shown within the manuscript and figures. The raw data and the analysis details that support the findings of this study are available from the corresponding author upon reasonable request.

-WILEY-

ORCID

Agam P. Singh D http://orcid.org/0000-0003-4262-2556

REFERENCES

- 1. W. H. O. World malaria report 2018.
- 2. Vogel G. Infectious diseases. The genetics of resistant malaria. Science. 2014;346(6215):1276-1277.
- 3. Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat Med. 2017;23(8):917-928.
- 4. Das S, Saha B, Hati AK, Roy S. Evidence of artemisininresistant Plasmodium falciparum malaria in eastern India. N Engl J Med. 2018;379(20):1962-1964.
- 5. Noedl H, Se Y, Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359(24):2619-2620.
- 6. Healer J, Cowman AF, Kaslow DC, Birkett AJ. Vaccines to accelerate malaria elimination and eventual eradication. Cold Spring Harb Perspect Med. 2017:7:9.
- 7. Hoffman SL, Goh LML, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. 2002;185(8):1155-1164.
- 8. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature. 1967;216(5111):160-162.
- 9. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci. 1973;266(3):169-177.
- 10. Clyde DF, McCarthy VC, Miller RM, Hornick RB. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci. 1973;266(6):398-403.
- 11. Rieckmann KH, Beaudoin RL, Cassells JS, Sell KW. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ. 1979;57(suppl 1):261-265.
- 12. Itsara LS, Zhou Y, Do J, Grieser AM, Vaughan AM, Ghosh AK. The development of whole sporozoite vaccines for Plasmodium falciparum malaria. Front Immunol. 2018;9:2748.
- 13. Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R, Nussenzweig V. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature. 1987; 330(6149):664-666.
- 14. Bijker EM, Borrmann S, Kappe SH, Mordmuller B, Sack BK, Khan SM. Novel approaches to whole sporozoite vaccination against malaria. Vaccine. 2015;33(52):7462-7468.
- 15. Huzair F, Sturdy S. Biotechnology and the transformation of vaccine innovation: the case of the hepatitis B vaccines 1968-2000. Stud Hist Philos Biol Biomed Sci. 2017;64:11-21.
- 16. Patarroyo ME, Amador R, Clavijo P, et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature. 1988;332(6160):158-161.
- 17. Cummings JF, Spring MD, Schwenk RJ, et al. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T

cells but does not protect against experimental Plasmodium falciparum infection. Vaccine. 2010;28(31):5135-5144.

- 18. Ogwang C, Afolabi M, Kimani D, et al. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLOS One. 2013;8(3):e57726.
- 19. Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J. 2009;8:312.
- 20. Bauffe F, Desplans J, Fraisier C, Parzy D. Real-time PCR assay for discrimination of Plasmodium ovale curtisi and Plasmodium ovale wallikeri in the Ivory Coast and in the Comoros Islands. Malar J. 2012;11:307.
- 21. Joshi MB, Gam AA, Boykins RA, et al. Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates. Infect Immun. 2001;69(8): 4884-4890.
- 22. Jaijyan DK, Singh H, Singh AP. A sporozoite- and liver stageexpressed tryptophan-rich protein plays an auxiliary role in plasmodium liver stage development and is a potential vaccine candidate. J Biol Chem. 2015;290(32):19496-19511.
- 23. Haste Andersen P, Nielsen M, Lund O. Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci. 2006;15(11):2558-2567.
- 24. Frimpong A, Kusi KA, Ofori MF, Ndifon W. Novel strategies for malaria vaccine design. Front Immunol. 2018;9:2769.
- 25. Mahajan B, Berzofsky JA, Boykins RA, et al. Multiple antigen peptide vaccines against Plasmodium falciparum malaria. Infect Immun. 2010;78(11):4613-4624.
- 26. Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide vaccine: progress and challenges. Vaccines. 2014;2(3):515-536.
- 27. Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA. Fundamentals and methods for T- and B-cell epitope prediction. J Immunol Res. 2017;2017:2680160.
- 28. Matuschewski K. Murine infection models for vaccine development: the malaria example. Human Vaccin Immunother. 2013;9(3):450-456.
- 29. Nganou-Makamdop K, van Gemert GJ, Arens T, Hermsen CC, Sauerwein RW. Long term protection after immunization with P. berghei sporozoites correlates with sustained IFNgamma responses of hepatic CD8+ memory T cells. PLOS One. 2012; 7(5):e36508.
- 30. Reyes-Sandoval A, Berthoud T, Alder N, et al. Prime-boost immunisation with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun. 2010;78(1):145-153.

How to cite this article: Quadiri A, Kalia I, Kashif M, Singh AP. Identification and characterization of protective CD8⁺ T-epitopes in a malaria vaccine candidate SLTRiP. Immun Inflamm Dis. 2020;8:50-61. https://doi.org/10.1002/iid3.283